AU2001282129A1 - Hydroxamate derivatives useful as deacetylase inhibitors - Google Patents
Hydroxamate derivatives useful as deacetylase inhibitorsInfo
- Publication number
- AU2001282129A1 AU2001282129A1 AU2001282129A AU2001282129A AU2001282129A1 AU 2001282129 A1 AU2001282129 A1 AU 2001282129A1 AU 2001282129 A AU2001282129 A AU 2001282129A AU 2001282129 A AU2001282129 A AU 2001282129A AU 2001282129 A1 AU2001282129 A1 AU 2001282129A1
- Authority
- AU
- Australia
- Prior art keywords
- aryl
- alkyl
- heteroaryl
- heterocycloalkyl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
PEACETYLASE INHIBITORS
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. The inventive compounds are useful as pharmaceuticals for the treatment of proliferative diseases.
Background
Reversible acetylation of histones is a major regulator of gene expression that acts by altering accessibility of transcription factors to DNA. In normal cells, histone deacetylase (HDA) and histone acetyltrasferase together control the level of acetylation of histones to maintain a balance. Inhibition of HDA results in the accumulation of hyperacetylated histones, which results in a variety of cellular responses.
Inhibitors of HDA have been studied for their therapeutic effects on cancer cells. For example, butyric acid and its derivatives, including sodium phenylbutyrate, have been reported to induce apoptosis in vitro in human colon carcinoma, leukemia and retinoblastoma cell lines. However, butyric acid and its derivatives are not useful pharmacological agents because they tend to be metabolized rapidly and have a very short half-life in vivo. Other inhibitors of HDA that have been widely studied for their anti-cancer activities are trichostatin A and trapoxin. Trichostatin A is an antifungal and antibiotic and is a reversible inhibitor of mammalian HDA. Trapoxin is a cyclic tetrapeptide, which is an irreversible inhibitor of mammalian HDA. Although trichostatin and trapoxin have been studied for their anti-cancer activities, the in vivo instability of the compounds makes them less suitable as anti-cancer drugs. There remains a need for an active compound that is suitable for treating tumors, including cancerous tumors, that is highly efficacious and stable.
Summary
The present invention provides efficacious deacetylase inhibitor compounds that are useful as pharmaceutical agents having the formula I
wherein
Ri is H, halo, or a straight chain C C6 alkyl (especially methyl, ethyl or π-propyl, which methyl, ethyl and n-propyl substituents are unsubstituted or substituted by one or more substituents described below for alkyl substituents);
R2 is selected from H, C1-C10 alkyl, (e.g. methyl, ethyl or -CH2CH2-OH), C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, C - C9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), aryl, heteroaryl, arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), -(CH2)„C(O)R6, -(CH2)nOC(O)R6, amino acyl, HON-C(O)-CH=C(R1)- aryl-alkyl- and -(CH2)nR7;
R3 and R4 are the same or different and independently H, CrC6 alkyl, acyl or acylamino, or R3 and R4 together with the carbon to which they are bound represent C=O, C=S, or C=NR8, or R2 together with the nitrogen to which it is bound and R3 together with the carbon to which it is bound can form a C - Cg heterocycloalkyl, a heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring;
R5 is selected from H, C C6 alkyl, C - C9 cycloalkyl, C - C9 heterocycloalkyl, acyl, aryl, heteroaryl, arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), aromatic polycycles, non-aromatic polycycles, mixed aryl and non-aryl polycycles, polyheteroaryl, non-aromatic polyheterocycles, and mixed aryl and non-aryl polyheterocycles; n, n1( n2 and n3 are the same or different and independently selected from 0 - 6, when ni is 1-6, each carbon atom can be optionally and independently substituted with R3 and/or R4;
X and Y are the same or different and independently selected from H, halo, C.-C alkyl, such as CH3 and CF3> NO2, C(O)Rι, OR9, SR9, ON, and NR.0R..;
R6 is selected from H, Cι-C6 alkyl, C4 - C9 cyc\oalky\, C4 - C9 heterocycloalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), aryl, heteroaryl, arylalkyl (e.g., benzyl, 2- phenylethenyl), heteroarylalkyl (e.g., pyridylmethyl), OR12, and NRι ι4; R7 is selected from OR15) SRι5, S(O)R16, SO2Rι7, NR13Rι4, and NR12SO2R6; R8 is selected from H, OR15, NRι3Rι4, C C6 alkyl, C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), and heteroarylalkyl (e.g., pyridylmethyl); R9 is selected from Cι - C alkyl, for example, CH3 and CF3, C(O)-alkyl, for example
C(O)CH3, and C(O)CF3; R10 and Rn are the same or different and independently selected from H, Cι-C4 alkyl, and -C(O)-alkyl; R12 is selected from H, CrC6 alkyl, C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, C4 - C9 heterocycloalkylalkyl, aryl, mixed aryl and non-aryl polycycle, heteroaryl, arylalkyl
(e.g., benzyl), and heteroarylalkyl (e.g., pyridylmethyl); R13 and R14 are the same or different and independently selected from H, C C6 alkyl,
C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), heteroarylalkyl (e.g., pyridylmethyl), amino acyl, or R13 and R14 together with the nitrogen to which they are bound are C - C9 heterocycloalkyl, heteroaryl, polyheteroaryl, non-aromatic polyheterocycle or mixed aryl and non-aryl polyheterocycle; Ri5 is selected from H, Ci-Ce alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZR12; Rie is selected from CrC6 alkyl, C - C9 cycloalkyl, C - C9 heterocycloalkyl, aryl, heteroaryl, polyheteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZRι2; Rι7 is selected from CrC6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, aromatic polycycles, heteroaryl, arylalkyl, heteroarylalkyl, polyheteroaryl and
m is an integer selected from 0 to 6; and Z is selected from O, NR13, S and S(O), or a pharmaceutically acceptable salt thereof.
The compounds of the present invention are suitable as active agents in pharmaceutical compositions that are efficacious particularly for treating cellular proliferative ailments. The pharmaceutical composition has a pharmaceutically effective amount of the
present active agent along with other pharmaceutically acceptable exipients, carriers, fillers, diluents and the like. The term pharmaceutically effective amount as used herein indicates an amount necessary to administer to a host to achieve a therapeutic result, especially an anti-tumor effect, e.g., inhibition of proliferation of malignant cancer cells, benign tumor cells or other proliferative cells.
Detailed Description
The present invention provides hydroxamate compounds, e.g., hydroxamic acids, that are inhibitors of deacetylases, preferably inhibitors of histone deacetylases. The hydroxamate compounds are highly suitable for treating tumors, including cancerous tumors. The hydroxamate compounds of the present invention have the following structure I
wherein
R. is H, halo, or a straight chain CrC6 alkyl (especially methyl, ethyl or n-propyl, which methyl, ethyl and n-propyl substituents are unsubstituted or substituted by one or more substituents described below for alkyl substituents);
R2 is selected from H, C1-C10 alkyl, (preferably Cι-C6 alkyl, e.g. methyl, ethyl or -CH2CH2-OH), C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, C4 - C9 heterocycloalkylalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), aryl, heteroaryl, arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), -(CH2)nC(O)R6, -(CH2)nOC(O)R6, amino acyl, HON-C(O)-CH=C(R1)-aryl-alkyl- and -(CH2)nR7;
R3 and R4 are the same or different and independently H, C C6 alkyl, acyl or acylamino, or R3 and R4 together with the carbon to which they are bound represent C=O, C=S, or C=NR8, or R2 together with the nitrogen to which it is bound and R3 together with the carbon to which it is bound can form a C4 - C9 heterocycloalkyl, a
heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring; R5 is selected from H, CrC6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, acyl, aryl, heteroaryl, arylalkyl (e.g. benzyl), heteroarylalkyl (e.g. pyridylmethyl), aromatic polycycles, non-aromatic polycycles, mixed aryl and non-aryl polycycles, polyheteroaryl, non-aromatic polyheterocycles, and mixed aryl and non-aryl polyheterocycles; n, n1( n2 and n3 are the same or different and independently selected from 0 - 6, when ni is 1-6, each carbon atom can be optionally and independently substituted with R3 and/or R4; X and Y are the same or different and independently selected from H, halo, CrC4 alkyl, such as CH3 and CF3> NO2, C(O)Rι, OR9, SR9, CN, and NR10R11; R6 is selected from H, C C6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), aryl, heteroaryl, arylalkyl (e.g., benzyl, 2- phenylethenyl), heteroarylalkyl (e.g., pyridylmethyl), ORι2, and NRι3R14; R7 is selected from ORι5) SRι5, S(O)R16, SO2Ri7, NRι3R14, and NR12SO2Re; R8 is selected from H, ORι5, NR 3Rι4, C C6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), and heteroarylalkyl (e.g., pyridylmethyl); R9 is selected from Ci - C alkyl, for example, CH3 and CF3, C(O)-alkyl, for example
C(O)CH3, and C(O)CF3; Rio and Rn are the same or different and independently selected from H, Cι-C alkyl, and -C(O)-alkyl; R12 is selected from H, CrC6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, C4 - C9 heterocycloalkylalkyl, aryl, mixed aryl and non-aryl polycycle, heteroaryl, arylalkyl
(e.g., benzyl), and heteroarylalkyl (e.g., pyridylmethyl); R13 and R are the same or different and independently selected from H, CrC6 alkyl,
C4- C9 cycloalkyl, C4- Cg heterocycloalkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), heteroarylalkyl (e.g., pyridylmethyl), amino acyl, or R 3 and Rι together with the nitrogen to which they are bound are C - C9 heterocycloalkyl, heteroaryl, polyheteroaryl, non-aromatic polyheterocycle or mixed aryl and non-aryl polyheterocycle; R15 is selected from H, CrC6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZRι2;
Rιe is selected from d-C6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, polyheteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZRι2;
R17 is selected from C C6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, aromatic polycycles, heteroaryl, arylalkyl, heteroarylalkyl, polyheteroaryl and NR13Rι4; m is an integer selected from 0 to 6; and
Z is selected from O, NR13, S and S(O), or a pharmaceutically acceptable salt thereof.
As appropriate, unsubstituted means that there is no substituent or that the only substituents are hydrogen.
Halo substituents are selected from fluoro, chloro, bromo and iodo, preferably fluoro or chloro.
Alkyl substituents include straight and branched CrC6alkyl, unless otherwise noted. Examples of suitable straight and branched Cι-C6alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl, and the like. Unless otherwise noted, the alkyl substituents include both unsubstituted alkyl groups and alkyl groups that are substituted by one or more suitable substituents, including unsaturation (i.e. there are one or more double or triple C-C bonds), acyl, cycloalkyl, halo, oxyalkyl, alkylamino, aminoalkyl, acylamino and ORι5, for example, alkoxy. Preferred substituents for alkyl groups include halo, hydroxy, alkoxy, oxyalkyl, alkylamino, and aminoalkyl.
Cycloalkyl substituents include C3-C9 cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, unless otherwise specified. Unless otherwise noted, cycloalkyl substituents include both unsubstituted cycloalkyl groups and cycloalkyl groups that are substituted by one or more suitable substituents, including CrC6 alkyl, halo, hydroxy, aminoalkyl, oxyalkyl, alkylamino, and ORι5, such as alkoxy. Preferred substituents for cycloalkyl groups include halo, hydroxy, alkoxy, oxyalkyl, alkylamino and aminoalkyl.
The above discussion of alkyl and cycloalkyl substituents also applies to the alkyl portions of other substituents, such as without limitation, alkoxy, alkyl amines, alkyl ketones, arylalkyl, heteroarylalkyl, alkylsulfonyl and alkyl ester substituents and the like.
Heterocycloalkyl substituents include 3 to 9 membered aliphatic rings, such as 4 to 7 membered aliphatic rings, containing from one to three heteroatoms selected from nitrogen, sulfur and oxygen. Examples of suitable heterocycloalkyl substituents include pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1 ,3-diazapane, 1 ,4-diazapane, 1 ,4-oxazepane, and 1 ,4-oxathiapane. Unless otherwise noted, the rings are unsubstituted or substuted on the carbon atoms by one or more suitable substituents, including CrC6 alkyl, C - C9 cycloalkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), and heteroarylalkyl (e.g., pyridylmethyl), halo, amino, alkyl a ino and OR15, for example alkoxy. Unless otherwise noted, nitrogen heteroatoms are unsubstituted or substituted by H, d-C4 alkyl, arylalkyl (e.g., benzyl), and heteroarylalkyl (e.g., pyridylmethyl), acyl, aminoacyl, alkylsulfonyl, and arylsulfonyl.
Cycloalkylalkyl substituents include compounds of the formula -(CH2)n5-cycloalkyl wherein n5 is a number from 1-6. Suitable cycloalkylalkyl substituents include cyclopentylmethyl-, cyclopentylethyl, cyclohexylmethyl and the like. Such substituents are unsubstituted or substituted in the alkyl portion or in the cycloalkyl portion by a suitable substituent, including those listed above for alkyl and cycloalkyl.
Aryl substituents include unsubstituted phenyl and phenyl substituted by one or more suitable substituents, including C C6 alkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), O(CO)alkyl, oxyalkyl, halo, nitro, amino, alkylamino, aminoalkyl, alkyl ketones, nitrile, carboxyalkyl, alkylsulfonyl, aminosulfonyl, arylsulfonyl, and ORι5, such as alkoxy. Preferred substituents include including Cι-C6 alkyl, cycloalkyl (e.g., cyclopropylmethyl), alkoxy, oxyalkyl, halo, nitro, amino, alkylamino, aminoalkyl, alkyl ketones, nitrile, carboxyalkyl, alkylsulfonyl, arylsulfonyl, and aminosulfonyl. Examples of suitable aryl groups include C C4alkylphenyl, CrC alkoxyphenyl, trifluoromethylphenyl, methoxyphenyl, hydroxyethylphenyl, dimethylaminophenyl, aminopropylphenyl, carbethoxyphenyl, methanesulfonylphenyl and tolylsulfonylphenyl.
Aromatic polycycles include naphthyl, and naphthyl substituted by one or more suitable substituents, including CrC6 alkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), oxyalkyl, halo, nitro, amino, alkylamino, aminoalkyl, alkyl ketones, nitrile, carboxyalkyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl and ORι5, such as alkoxy.
Heteroaryl substituents include compounds with a 5 to 7 member aromatic ring containing one or more heteroatoms, for example from 1 to 4 heteroatoms, selected from N, O and S. Typical heteroaryl substituents include furyl, thienyl, pyrrole, pyrazole, triazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, pyrazine and the like. Unless otherwise noted, heteroaryl substituents are unsubstituted or substituted on a carbon atom by one or more suitable substituents, including alkyl, the alkyl substituents identified above, and another heteroaryl substituent. Nitrogen atoms are unsubstituted or substituted, for example by Rι3; especially useful N substituents include H, Ci - C alkyl, acyl, aminoacyl, and sulfonyl.
Arylalkyl substituents include groups of the formula -(CH2)n5-aryl, -(CH2)n5-r (CHaryl)-(CH2)n5-aryl or -(CH2)n5.ιCH(aryl)(aryl) wherein aryl and n5 are as defined above. Such arylalkyl substituents include benzyl, 2-phenylethyl, 1-phenylethyl, tolyl-3-propyl, 2- phenylpropyl, diphenylmethyl, 2-diphenylethyl, 5,5-dimethyl-3-phenylpentyl and the like. Arylalkyl substituents are unsubstituted or substituted in the alkyl moiety or the aryl moiety or both as described above for alkyl and aryl substituents.
Heteroarylalkyl substituents include groups of the formula -(CH2)n5-heteroaryl wherein heteroaryl and n5 are as defined above and the bridging group is linked to a carbon or a nitrogen of the heteroaryl portion, such as 2-, 3- or 4-pyridylmethyl, imidazolylmethyl, quinolylethyl, and pyrrolylbutyl. Heteroaryl substituents are unsubstituted or substituted as discussed above for heteroaryl and alkyl substituents.
Amino acyl substituents include groups of the formula -C(O)-(CH2)n-C(H)(NR13R14)- (CH2)n-R5 wherein n, Rι3, R and R5 are described above. Suitable aminoacyl substituents include natural and non-natural amino acids such as glycinyl, D-tryptophanyl, L-lysinyl, D- or L-homoserinyl, 4-aminobutryic acyl, ±-3-amin-4-hexenoyl.
Non-aromatic polycycle substituents include bicyclic and tricyclic fused ring systems where each ring can be 4-9 membered and each ring can contain zero, 1 or more double and/or triple bonds. Suitable examples of non-aromatic polycycles include decalin, octahydroindene, perhydrobenzocycloheptene, perhydrobenzo-[t]-azulene. Such substituents are unsubstituted or substituted as described above for cycloalkyl groups.
Mixed aryl and non-aryl polycycle substituents include bicyclic and tricyclic fused ring systems where each ring can be 4 - 9 membered and at least one ring is aromatic. Suitable examples of mixed aryl and non-aryl polycycles include methylenedioxyphenyl, bis- methylenedioxyphenyl, 1 ,2,3,4-tetrahydronaphthalene, dibenzosuberane, dihdydroanthracene, 9H-fluorene. Such substituents are unsubstituted or substituted by nitro or as described above for cycloalkyl groups.
Polyheteroaryl substituents include bicyclic and tricyclic fused ring systems where each ring can independently be 5 or 6 membered and contain one or more heteroatom, for example, 1 , 2, 3, or 4 heteroatoms, chosen from O, N or S such that the fused ring system is aromatic. Suitable examples of polyheteroaryl ring systems include quinoline, isoquinoline, pyridopyrazine, pyrrolopyridine, furopyridine, indole, benzofuran, benzothiofuran, benzindole, benzoxazole, pyrroloquinoline, and the like. Unless otherwise noted, polyheteroaryl substituents are unsubstituted or substituted on a carbon atom by one or more suitable substituents, including alkyl, the alkyl substituents identified above and a substituent of the formula -O-(CH2CH=CH(CH3)(CH2))1.3H. Nitrogen atoms are unsubstituted or substituted, for example by Rι3; especially useful N substituents include H, Ci - C4 alkyl, acyl, aminoacyl, and sulfonyl.
Non-aromatic polyheterocyclic substituents include bicyclic and tricyclic fused ring systems where each ring can be 4 - 9 membered, contain one or more heteroatom, for example, 1 , 2, 3, or 4 heteroatoms, chosen from O, N or S and contain zero or one or more C-C double or triple bonds. Suitable examples of non-aromatic polyheterocycles include hexitol, cis-perhydro-cyclohepta[b]pyridinyl, decahydro-benzo[f][1 ,4]oxazepinyl, 2,8- dioxabicyclo[3.3.0]octane, hexahydro-thieno[3,2-b]thiophene, perhydropyrrolo[3,2-b]pyrrole, perhydronaphthyridine, perhydro-1H-dicyclopenta[b,e]pyran. Unless otherwise noted, non- aromatic polyheterocyclic substituents are unsubstituted or substituted on a carbon atom by one or more substituents, including alkyl and the alkyl substituents identified above.
Nitrogen atoms are unsubstituted or substituted, for example, by Rι3; especially useful N substituents include H, Ci - C alkyl, acyl, aminoacyl, and sulfonyl.
Mixed aryl and non-aryl polyheterocycles substituents include bicyclic and tricyclic fused ring systems where each ring can be 4 - 9 membered, contain one or more heteroatom chosen from O, N or S, and at least one of the rings must be aromatic. Suitable examples of mixed aryl and non-aryl polyheterocycles include 2,3-dihydroindole, 1,2,3,4- tetrahydroquinoline, 5,11-dihydro-10H-dibenz[b,e][1 ,4]diazepine, 5H- dibenzo[b,e][1 ,4]diazepine, 1 ,2-dihydropyrrolo[3,4-b][1 ,5]benzodiazepine, 1 ,5-dihydro- pyrido[2,3-b][1 ,4]diazepin-4-one, 1 ,2,3,4,6,11 -hexahydro-benzo[b]pyrido[2,3- e][1 ,4]diazepin-5-one. Unless otherwise noted, mixed aryl and non-aryl polyheterocyclic substituents are unsubstituted or substituted on a carbon atom by one or more suitable substituents, including, -N-OH, =N-OH, alkyl and the alkyl substituents identified above. Nitrogen atoms are unsubstituted or substituted, for example, by R13; especially useful N substituents include H, Ci - C alkyl, acyl, aminoacyl, and sulfonyl.
Amino substituents include primary, secondary and tertiary amines and in salt form, quaternary amines. Examples of amino substituents include mono- and di-alkylamino, mono- and di-aryl amino, mono- and di-arylalkyl amino, aryl-arylalkylamino, alkyl-arylamino, alkyl-arylalkylamino and the like.
Sulfonyl substituents include alkylsulfonyl and arylsulfonyl, for example methane sulfonyl, benzene sulfonyl, tosyl and the like.
Acyl substituents include groups of the formula -C(O)-W, -OC(O)-W, -C(O)-O-W and -C(O)NR13Rι4, where W is R16, H or cycloalkylalkyl.
Acylamino substituents include groups of the formula -N(Rι2)C(O)-W, -N(Rι2)C(O)- O-W, and -N(R12)C(O)-NHOH and Rι2 and W are as defined above.
The R2 substituent HON-C(O)-CH=C(Rι)-aryl-alkyl- is a group of the formula
wherein n4 is 0-3 and X and Y are as defined above.
Preferences for each of the substituents include the following: Ri is H, halo, or a straight chain d-C alkyl; R2 is selected from H, C C6 alkyl, C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, -(CH2)nC(O)R6, amino acyl, and -(CH2)nR7; R3 and R are the same or different and independently selected from H, and C C6 alkyl, or R3 and R4 together with the carbon to which they are bound represent C=O,
C=S, or C=NR8; R5 is selected from H, CrC6 alkyl, C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, an aromatic polycycle, a non-aromatic polycycle, a mixed aryl and non-aryl polycycle, polyheteroaryl, a non-aromatic polyheterocycle, and a mixed aryl and non-aryl polyheterocycle; n, ni, n2 and n3 are the same or different and independently selected from 0 - 6, when ni is 1-6, each carbon atom is unsubstituted or independently substituted with R3 and/or R4; X and Y are the same or different and independently selected from H, halo, C C4 alkyl,
CF3, NO2, C(O)Rι, OR9, SR9, CN, and NRioRn; R6 is selected from H, CrC6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, ORι2, and NRι3Rι4; R7 is selected from ORι5, SRι5, S(O)Rι6, SO2R17, NRi3Rι4, and NRι2SO2R6; Rs is selected from H, OR 5, NR 3Rι4, CrC6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; R9 is selected from Ci - C4 alkyl and C(O)-alkyl; Rio and Rn are the same or different and independently selected from H, CrC4 alkyl, and -C(O)-alkyl;
Rι2 is selected from H, Ci-Ce alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; R13 and R14 are the same or different and independently selected from H, Cι-C6 alkyl,
C4- C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and amino acyl; R15 is selected from H, d-Ce alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZRι2; Rιe is selected from Cι-C6 alkyl, C - C9 cycloalkyl, C - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZRι2; Rι7 is selected from CrC6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and NRι3Rι4; m is an integer selected from 0 to 6; and Z is selected from O, NR13, S, S(O).
Useful compounds of the formula I include those wherein each of Ri, X, Y, R3, and R is H, including those wherein one of n2 and n3 is zero and the other is 1 , especially those wherein R2 is H or -CH2-CH2-OH.
One suitable genus of hydroxamate compounds are those of formula la
wherein n4 is 0-3,
R2 is selected from H, Cι-C6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, -(CH2)nC(O)Re, amino acyl and -(CH2)nR7; R5' is heteroaryl, heteroarylalkyl (e.g., pyridylmethyl), aromatic polycycles, non-aromatic polycycles, mixed aryl and non-aryl polycycles, polyheteroaryl, or mixed aryl and non-aryl polyheterocycles, or a pharmaceutically acceptable salt thereof.
Another suitable genus of hydroxamate compounds are those of formula la
wherein n4 is 0-3,
R2 is selected from H, Cι-C6 alkyl, C4 - Cg cycloalkyl, C4 - Cg heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, -(CH2)nC(O)R6, amino acyl and -(CH2)nR7;
R5' is aryl, arylalkyl, aromatic polycycles, non-aromatic polycycles, and mixed aryl and non-aryl polycycles; especially aryl, such as p-fluorophenyl, p-chlorophenyl, p-O-C C4-alkylphenyl, such as p-methoxyphenyl, and p-CrC4-alkylphenyl; and arylalkyl, such as benzyl, ortho, meta or para-i luorobenzyl, ortho, meta or para-chlorobenzyl, ortho, meta or para-mono, di or tri-O-Cι-C -alkylbenzyl, such as ortho, meta orpara- methoxybenzyl, /77,p-diethoxybenzyl, o,m,p-triimethoxybenzyl , and ortho, meta or para- mono, di or tri CrC4-alkylphenyl, such as p-methyl, m, -diethylphenyl, or a pharmaceutically acceptable salt thereof.
Another interesting genus are the compounds of formula lb
wherein
R2' is selected from H, C C6 alkyl, C4-C6 cycloalkyl, cycloalkylalkyl (e.g., cyclopropylmethyl), -(CH2)2-4θR2ι where R2ι is H, methyl, ethyl, propyl, and Apropyl, and
R5" is unsubstituted 1 H-indol-3-yl, benzofuran-3-yl or quinolin-3-yl, or substituted 1 /-/-indol- 3-yl, such as 5-fluoro-1 H-indol-3-yl or 5-methoxy-1 H-indol-3-yl, benzofuran-3-yl or quinolin- 3-yl, or a pharmaceutically acceptable salt thereof.
Another interesting genus of hydroxamate compounds are the compounds of formula lc
wherein the ring containing Z is aromatic or non-aromatic, which non-aromatic rings are saturated or unsaturated,
Z is O, S or N-Rso,
Rι8 is H, halo, Cι-C6alkyl (methyl, ethyl, t-butyl), C3-C7cycloalkyl, aryl, for example unsubstituted phenyl or phenyl substituted by 4-OCH3 or 4-CF3, or heteroaryl, such as 2-furanyl, 2-thiophenyl or 2-, 3- or 4-pyridyl;
R20 is H, Cι-C6alkyl, CrCealkyl-Qr-Cgcycloalkyl (e.g., cyclopropylmethyl), aryl, heteroaryl, arylalkyl (e.g., benzyl), heteroarylalkyl (e.g., pyridylmethyl), acyl (acetyl, propionyl, benzoyl) or sulfonyl (methanesulfonyl, ethanesulfonyl, benzenesulfonyl, toluenesulfonyl);
A1 is 1 , 2 or 3 substituents which are independently H, Cι-C-6alkyl, -ORι9, halo, alkylamino, aminoalkyl, halo, or heteroarylalkyl (e.g., pyridylmethyl),
Rig is selected from H, Cι-C6alkyl, C -C9cycloalkyl, C -C9heterocycloalkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), heteroarylalkyl (e.g., pyridylmethyl) and
-(CH2CH=CH(CH3)(CH2))i.3H;
R2 is selected from H, CrC6 alkyl, C - Cg cycloalkyl, C4 - C9 heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, -(CH2)nC(O)R6, amino acyl and -(CH2)nR7; v is 0, 1 or 2, p is 0-3, and q is 1 -5 and r is 0 or q is 0 and r is 1 -5, or a pharmaceutically acceptable salt thereof. The other variable substituents are as defined above.
Especially useful compounds of formula lc are those wherein R2 is H, or -(CH2)PCH2QH, wherein p is 1-3, especially those wherein Ri is H; such as those wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3, especially those wherein Zi is N-R20. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1.
Another interesting genus of hydroxamate compounds are the compounds of formula Id
wherein
R18 is H, halo, CrCealkyl (methyl, ethyl, t-butyl), C3-C7cycloalkyl, aryl, for example, unsubstituted phenyl or phenyl substituted by 4-OCH3 or 4-CF3, or heteroaryl,
R20 is H, Cι-C6alkyl, Ci-Cealkyl-Cr-Cgcycloalkyl (e.g., cyclopropylmethyl), aryl, heteroaryl, arylalkyl (e.g., benzyl), heteroarylalkyl (e.g., pyridylmethyl), acyl (acetyl, propionyl, benzoyl) or sulfonyl (methanesulfonyl, ethanesulfonyl, benzenesulfonyl, toluenesulfonyl);
A1 is 1 , 2 or 3 substituents which are independently H, Cι-C-6alkyl, -ORι9, or halo,
Rι9 is selected from H, Cι-C6alkyl, C4-C9cycloalkyl, C4-C9heterocycloalkyl, aryl, heteroaryl, arylalkyl (e.g., benzyl), and heteroarylalkyl (e.g., pyridylmethyl); p is 0-3, and q is 1 -5 and r is 0 or q is O and r is 1-5, or a pharmaceutically acceptable salt thereof. The other variable substituents are as defined above.
Especially useful compounds of formula Id are those wherein R2 is H, or -(CH2)pCH2OH, wherein p is 1 -3, especially those wherein Ri is H; such as those wherein Ri is H and X and Y are each H, and wherein q is 1 -3 and r is 0 or wherein q is 0 and r is 1 -3. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1.
The present invention further relates to compounds of the formula le
or a pharmaceutically acceptable salt thereof. The variable substituents are as defined above.
Especially useful compounds of formula le are those wherein Rι8 is H, fluoro, chloro, bromo, a Cι-C alkyl group, a substituted CrC4alkyl group, a C3-C7cycloalkyl group, unsubstituted phenyl, phenyl substituted in the para position, or a heteroaryl (e.g., pyridyl) ring.
Another group of useful compounds of formula le are those wherein R2 is H, or - (CH2)pCH2OH, wherein p is 1 -3, especially those wherein Rt is H; such as those wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1.
Another group of useful compounds of formula le are those wherein Rι8 is H, methyl, ethyl, t-butyl, trifluoromethyl, cyclohexyl, phenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 2-furanyl, 2-thiophenyl, or 2-, 3- or 4-pyridyl wherein the 2-furanyl, 2-thiophenyl and 2-, 3- or 4-pyridyl substituents are unsubstituted or substituted as described above for heteroaryl rings; R2 is H, or -(CH2)pCH2OH, wherein p is 1 -3; especially those wherein Ri is H and X and Y are each H, and wherein q is 1 -3 and r is 0 or wherein q is 0 and r is 1 -3. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1.
Those compounds of formula le wherein R20 is H or CrC6alkyl, especially H, are important members of each of the subgenuses of compounds of formula le described above.
N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]- 2£-2-propenamide, or a pharmaceutically acceptable salt thereof, are important compounds of formula le.
The present invention further relates to the compounds of the formula If
or a pharmaceutically acceptable salt thereof. The variable substituents are as defined above.
Useful compounds of formula If are those wherein R2 is H, or -(CH2)pCH2OH, wherein p is 1- 3, especially those wherein Ri is H; such as those wherein Ri is H and X and Y are each H, and wherein q is 1 -3 and r is 0 or wherein q is 0 and r is 1 -3. Among these compounds R2 is preferably H or -CH2-CH2-OH and the sum of q and r is preferably 1.
N-hydroxy-3-[4-[[[2-(benzofur-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide,or a pharmaceutically acceptable salt thereof, is an important compound of formula If.
The compounds described above are often used in the form of a pharmaceutically acceptable salt. Pharmaceutically acceptable salts include, when appropriate, pharmaceutically acceptable base addition salts and acid addition salts, for example, metal salts, such as alkali and alkaline earth metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts, and sulfonate salts. Acid addition salts include inorganic acid addition salts such as hydrochloride, sulfate and phosphate, and organic acid addition salts such as alkyl sulfonate, arylsulfonate, acetate, maleate, fumarate, tartrate, citrate and lactate. Examples of metal salts are alkali metal salts, such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt. Examples of ammonium salts are ammonium salt and tetramethylammonium salt. Examples of organic amine addition salts are salts with morpholine and piperidine. Examples of amino acid addition salts are salts with glycine, phenylalanine, glutamic acid and lysine. Sulfonate salts include mesylate, tosylate and benzene sulfonic acid salts.
As is evident to those skilled in the art, the many of the deacetylase inhibitor compounds of the present invention contain asymmetric carbon atoms. It should be understood, therefore, that the individual stereoisomers are contemplated as being included within the scope of this invention.
The hydroxamate compounds of the present invention can be produced by known organic synthesis methods. For example, the hydroxamate compounds can be produced
by reacting methyl 4-formyl cinnamate with tryptamine and then converting the reactant to the hydroxamate compounds. As an example, methyl 4-formyl cinnamate 2, is prepared by acid catalyzed esterification of 4-formylcinnamic acid 3 (Bull. Chem. Soc. Jpn. 1995; 68:2355-2362). An alternate preparation of methyl 4-formyl cinnamate 2 is by a Pd- catalyzed coupling of methyl acrylate 4 with 4-bromobenzaldehyde 5.
CHO
Additional starting materials can be prepared from 4-carboxybenzaldehyde 6, and an exemplary method is illustrated for the preparation of aldehyde 9, shown below. The carboxylic acid in 4-carboxybenzaldehyde 6 can be protected as a silyl ester (e.g., the t- butyldimethylsilyl ester) by treatment with a silyl chloride (e.g., f-butyldimethylsilyl chloride) and a base (e.g. triethylamine) in an appropriate solvent (e.g., dichloromethane). The resulting silyl ester 7 can undergo an olefination reaction (e.g., a Horner-Emmons olefination) with a phosphonate ester (e.g., triethyl 2-phosphonopropionate) in the presence of a base (e.g., sodium hydride) in an appropriate solvent (e.g., tetrahydrofuran (THF)). Treatment of the resulting diester with acid (e.g., aqueous hydrochloric acid) results in the hydrolysis of the silyl ester providing acid 8. Selective reduction of the carboxylic acid of 8 using, for example, borane-dimethylsuflide complex in a solvent (e.g., THF) provides an intermediate alcohol. This intermediate alcohol could be oxidized to aldehyde 9 by a number of known methods, including, but not limited to, Swern oxidation, Dess-Martin periodinane oxidation, Moffatt oxidation and the like.
The aldehyde starting materials 2 or 9 can be reductively aminated to provide secondary or tertiary amines. This is illustrated by the reaction of methyl 4-formyl cinnamate 2 with tryptamine 10 using sodium triacetoxyborohydride (NaBH(OAc)3) as the reducing agent in dichloroethane (DCE) as solvent to provide amine 11. Other reducing agents can be used, e.g., sodium borohydride (NaBH ) and sodium cyanoborohydride (NaBH3CN), in other solvents or solvent mixtures in the presence or absence of acid catalysts (e.g., acetic acid and trifluoroacetic acid). Amine 11 can be converted directly to hydroxamic acid 12 by treatment with 50% aqueous hydroxylamine in a suitable solvent (e.g., THF in the presence of a base, e.g., NaOH). Other methods of hydroxamate formation are known and include reaction of an ester with hydroxylamine hydrochloride and a base (e.g., sodium hydroxide or sodium methoxide) in a suitable solvent or solvent mixture (e.g., methanol, ethanol or methanol/THF).
Aldehyde 2 can be reductively aminated with a variety of amines, exemplified by, but not limited to, those illustrated in Table 1. The resulting esters can be converted to target hydroxamates by the methods listed.
Table 1
An alternate synthesis of the compounds of this invention starts by reductive amination of 4-formyl cinnamic acid 3, illustrated below with 3-phenylpropylamine 13, using, for example, NaBH3CN as the reducing agent in MeOH and HOAc as a catalyst. The basic nitrogen of the resulting amino acid 14 can be protected, for example, as f-butoxycarbamate (BOC) by reaction with di-f-butyldicarbonate to give 15.
NaBH.CN ° (BOC^O/Et-N 3 + Ph(CH2)3NH> , BOC *τ^-Λ~ OH I OH
Dioxane/H20 Ph(CH2)3N . J
13 AcOH/ eOH Ph .
14 15
The carboxylic acid can be coupled with a protected hydroxylamine (e.g., O-trityl hydroxylamine) using a dehydrating agent (e.g., 1 -(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (EDCI)) and a catalyst (e.g., 1 -hydroxybenzotriazole hydrate (HOBT)) in a suitable solvent (e.g., DMF) to produce 16. Treatment of 16 with a strong acid (e.g., trifluoroacetic acid (TFA)) provides a hydroxamic acid 17 of the present invention. Additional examples of compounds that can be prepared by this method are:
Tertiary amine compounds can be prepared by a number of methods. Reductive amination of 30 with nicotinaldehyde 32 using NaBH3CN as the reducing agent in dichloroethane and HOAc as a catalyst provides ester 34. Other reducing agents can be used (e.g., NaBH4 and NaBH(OAc)3 ) in other solvents or solvent mixtures in the presence or absence of acid catalysts (e.g., acetic acid, trifluoroacetic acid and the like). Reaction of ester 34 with HONH2»HCI, NaOH in MeOH provides hydroxamate 36.
Tertiary amine compounds prepared by this methodology are exemplified, but not limited to, those listed in Table 2.
Table 2
An alternate method for preparing tertiary amines is by reacting a secondary amine with an alkylating agent in a suitable solvent in the presence of a base. For example, heating a dimethylsulfoxide (DMSO) solution of amine 11 and bromide 40 in the presence of (APr)2NEt yielded tertiary amine 42. Reaction of the tertiary amine 42 with HONH2»HCI, NaOH in MeOH provides hydroxamate 43. The silyl group can be removed by any method
known to those skilled in the art. For example, the hydroxamate 43 can be treated with an acid, e.g., trifluoroacetic acid, or fluoride to produce hydroxyethyl compound 44.
O-TBDMS
(/-Pr)2NEt ^ COaMe HONH 2»HCI
11 + BrCH 2CH20-TBDMS 40 DMSO 42 NaOH, MeOH
N H
The hydroxamate compound, or salt thereof, is suitable for preparing pharmaceutical compositions, especially pharmaceutical compositions having deacetylase, especially histone deacetylase, inhibiting properties. Studies with athymic mice demonstrate that the hydroxamate compound causes HDA inhibition and increased histone acetylation in vivo, which triggers changes in gene expression that correlate with tumor growth inhibition.
The present invention further includes pharmaceutical compositions comprising a pharmaceutically effective amount of one or more of the above-described compounds as active ingredient. Pharmaceutical compositions according to the invention are suitable for enteral, such as oral or rectal, and parenteral administration to mammals, including man, for the treatment of tumors, alone or in combination with one or more pharmaceutically acceptable carriers.
The hydroxamate compound is useful in the manufacture of pharmaceutical compositions having an effective amount the compound in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredient together with (a) diluents; (b) lubricants, (c) binders (tablets); if desired, (d) disintegrants; and/or (e) absorbents, colorants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants,
such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, the compositions may also contain other therapeutically valuable substances. The compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain preferably about 1 to 50% of the active ingredient.
Suitable formulations also include formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a f reeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
As discussed above, the compounds of the present invention are useful for treating proliferative diseases. A proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases). The inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics; or (iii) a tumor that is refractory to treatment with other chemotherapeutics due to multidrug resistance.
In a broader sense of the invention, a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis,
atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis.
The compound is selectively toxic or more toxic to rapidly proliferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis. In addition, the hydroxamate compound induces p21 , cyclin-CDK interacting protein, which induces either apoptosis or G1 arrest in a variety of cell lines.
The following examples are intended to illustrate the invention and are not to be construed as being limitations thereto.
Example P1
Preparation of A/-Hydroxy-3-[4-[[[2-(1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2- propenamide.
4-formylcinnamic acid methylester is produced by adding 4-formyicinnamic acid (25 g, 0.143 mol) in MeOH and HCI (6.7 g, 0.18 mol). The resulting suspension is heated to reflux for 3 hours, cooled and evaporated to dryness. The resulting yellow solid is dissolved in EtOAc, the solution washed with saturated NaHCO3, dried (MgSO4) and evaporated to give a pale yellow solid which is used without further purification (25.0 g, 92%). To a solution of tryptamine (16.3 g, 100 mmol) and 4-formylcinnamic acid methylester (19 g, 100 mmol) in dichloroethane, NaBH(OAc)3 (21 g, 100 mmol) is added. After 4 hours the mixture is diluted with 10% K2CO3 solution, the organic phase separated and the aqueous solution extracted with CH2CI2. The combined organic extracts are dried (Na2SO ), evaporated and the residue purified by flash chromatography to produce 3-(4-{[2-(1 H-indol-3-yl)-ethylamino]- methyl}-phenyl)-(2£)-2-propenoic acid methyl ester (29 g). A solution of KOH (12.9 g 87%, 0.2 mol) in MeOH (100 mL) is added to a solution of HONH2»HCI (13.9 g, 0.2 mol) in MeOH (200 mL) and a precipitate results. After 15 minutes the mixture is filtered, the filter cake
washed with MeOH and the filtrate evaporated under vacuum to approximately 75 mL. The mixture is filtered and the volume adjusted to 100 mL with MeOH. The resulting solution 2M HONH2 is stored under N2 at -20° C for up to 2 weeks. Then 3-(4-{[2-(1 H-indol-3-yl)- ethylamino]-methyl}-phenyl)-(2£)-2-propenoic acid methyl ester (2.20 g, 6.50 mmol) is added to 2 M HONH2 in MeOH (30 mL, 60 mmol) followed by a solution of KOH (420 mg, 6.5 mmol) in MeOH (5 mL). After 2 hours dry ice is added to the reaction and the mixture is evaporated to dryness. The residue is dissolved in hot MeOH (20 mL), cooled and stored at -20 °C overnight. The resulting suspension is filtered, the solids washed with ice cold MeOH and dried under vacuum, producing Λ/-Hydroxy-3-[4-[[[2-(1 H-indol-3-yl)-ethyl]- amino]methyl]phenyl]-2E-2-propenamide (m/z 336 [MH+]).
Example P2
Preparation of Λ/-Hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indol-3-yl)-ethyl]- aminojmethyl]phenyl]-2E-2-propenamide
A solution of 3-(4-{[2-(1 /-/-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2£)-2-propenoic acid methyl ester (12.6 g, 37.7 mmol), (2-bromoethoxy)-tert-butyldimethylsilane (12.8 g, 53.6 mmol), (/-Pr)2NEt, (7.42 g, 57.4 mmol) in DMSO (100 mL) is heated to 50° C. After 8 hours the mixture is partitioned with CH2CI2/H2O. The organic layer is dried (Na2SO4) and evaporated. The residue is chromatographed on silica gel to produce 3-[4-({[2-(tøπ> butyIdimethylsilanyloxy)-ethyl]-[2-(1H-indol-3-yl)-ethyl]-amino}-methyl)-phenyl]-(2E)-2- propenoic acid methyl ester (13.1 g). Following the procedure described for the preparation of the hydroxamate compound in Example P1, 3-[4-({[2-(fert-butyldimethylsilanyloxy)-ethyl]- [2-(1 H-indol-3-yl)-ethyl]-amino}-methyl)-phenyl]-(2E)-2-propenoic acid methyl ester (5.4 g, 11 mmol) is converted to N-hydroxy-3-[4-({[2-(terf-butyldimethylsilanyloxy)-ethyl]-[2-(1 H- indol-3-yl)-ethyl]-amino}-methyl)-phenyl]-(2 -2-propenamide (5.1 g,) and used without further purification. The hydroxamic acid (5.0 g, 13.3 mmol) is then dissolved in 95% TFA/H2O (59 mL) and heated to 40 - 50 °C for 4 hours. The mixture is evaporated and the residue purified by reverse phase HPLC to produce Λ/-Hydroxy-3-[4-[[(2-hydroxyethyl)[2- (1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide as the trifluoroacetate salt (m/z 380 [MH+]).
Example P3
Preparation of N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E- 2-propenamide.
A suspension of LiAIH4 (17 g, 445 mmol) in dry THF (1000 mL) is cooled to 0 °C and 2- methylindole-3-glyoxylamide (30 g, 148 mmol) is added in portions over 30 min. The mixture is stirred at room temperature for 30 min. and then maintained at reflux for 3 h. The reaction is cooled to 0 °C and treated with H2O (17ml), 15% NaOH (aq., 17ml) and H2O (51ml). The mixture is treated with MgSO , filtered and the filtrate evaporated to give 2-methyltryptamine which is dissolved in MeOH. Methyl 4-formylcinnamate (16.9 g, 88.8 mmol) is added to the solution, followed by NaBH3CN (8.4 g) and AcOH (1 equiv.). After 1h the reaction is diluted with NaHCO3 (aq.) and extracted with EtOAc. The organic extracts are dried (MgSO4), filtered and evaporated. The residue is purified by chromatography to give 3-(4-{[2-(2- methyl-1 W-indo!-3-yl)-ethylamino]-methyl}-phenyl)-(2E)-2-propenoic acid methyl ester. The ester is dissolved in MeOH, 1.0 M HCI/dioxane (1 - 1.5 equiv.) is added followed by Et2O. The resulting precipitate is filtered and the solid washed with Et2O and dried thoroughly to give 3-(4-{[2-(2-methyl-1 -/-indol-3-yl)-ethylamino]-methyl}-phenyl)-(2E)-2-propenoic acid methyl ester hydrochloride. 1.0 M NaOH (aq., 85 mL) is added to an ice cold solution of the methyl ester hydrochloride (14.9 g, 38.6 mmol) and HONH2 (50% aq. solution, 24.0 mL, ca. 391.2 mmol). After 6 h, the ice cold solution is diluted with H2O and NH4CI (aq., 0.86 M, 100 mL). The resulting precipitate is filtered, washed with H2O and dried to afford N-hydroxy-3- [4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (m/z 350 [MH+]).
Examples 1-265
The following compounds are prepared by methods analogous to those disclosed in Examples P1 , P2 and P3:
The compounds of Examples 1-265 show an HDA enzyme IC50 in the range from about 0.005 to about 0.5 μM.
Example B1
Cell lines H1299 (human lung carcinoma cell) and HCT116 (colon tumor cell) are obtained from the American Type Culture Collection, Rockville, MD. The cell lines are free of Mycoplasma contamination (Rapid Detection System by Gen-Probe, Inc., San Diego, CA) and viral contamination (MAP testing by MA BioServices, Inc., Rockville, MD). The cell lines are propagated and expanded in RPM1 1640 medium containing 10% heat-inactivated FBS (Life Technologies, Grand Island, NY). Cell expansions for implantation are performed in cell factories (NUNC, purchased from Fisher Scientific, Springfield, NJ). Cells are harvested at 50-90% confluency, washed once with HBSS (Hank's Balanced Salt Solution) containing 10% FBS, and suspended in 100% HBSS.
Cell proliferation is measured with a commercial MTS kit (Promega, Madision, Wis.) assay using an adaptation of published procedures, for example, that disclosed in Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay, Alley MC, et al., Cancer Res. 1988; 48:589-601. Cells are plated in 96- well tissue culture dishes, with top and bottom rows left empty. H1299 and HCT116 cells
are suspended in complete media at a density of 5.3 x 103 and 3.6 x 103 cell/mL, respectively, and 190 μl are added per well. Each cell line is added to one half of the plate. Complete medium (200 μL) is added to the top and bottom rows. Twenty-four hours later, 10 μl of MTS solution is added to one of the plates to determine the activity at the time of compound addition (T0). The plate is incubated at 37 °C for 4 hours and the OD490 is measured on a Molecular Devices Thermomax at 490 nm using the Softmax program. The To plate serves as a reference for initial activity at the beginning of the experiment.
Five serial dilutions (1 :4) of each compound are made in a 96-deep well plate with the highest concentrations on the edge of plate. Two cell lines are tested with two compounds per plate. Ten microliters of each of the five dilutions are added in triplicate and complete medium alone is added to columns six and seven. The plates are incubated at 37 °C for 72 hours. The MTS solution is added (as for the T0 plate) and read four hours later.
In order to analyze the data, the average background value (media alone) is subtracted from each experimental well; the triplicate values are averaged for each compound dilution. The following formulas are used to calculate percent growth. If X > To, % Growth = ((X-T0)/(GC -T0)) x 100 If X < T0, % Growth = (X-T0) T0) x 100 in which T0 = (average value of cell viability at time 0) - background GC = average value of untreated cells (in triplicate) - background X = average value of compound treated cells (in triplicate) - background The "% Growth" is plotted against compound concentration and used to calculate IC50s employing the linear regression techniques between data points to predict the concentration of compounds at 50% inhibition.
Lactate salts of N-hydroxy-3-[4-[[[2-(1 W-indol-3-yl)-ethyl]-amino]methyl]phenylJ-2E-2- propenamide (CMD1), N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indol-3-yl)-ethyl]- amino]methyl]phenyl]-2E-2-propenamide (CMD2), N-hydroxy-3-[4-[[[2-(5-methoxy-1 H-indol- 3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD3), N-hydroxy-3-[4-[[[2-(5-fluoro- 1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD4), N-hydroxy-3-[4-[[[2- (benzofur-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (CMD5) having a purity of higher than 95% are dissolved in pure dimethylsulfoxide (DMSO) to create a stock solution. The stock solution is diluted with 5% dextrose injection, USP, just prior to dosing. In addition, N- (2-aminophenyl)-4-[N-pyridin-3-yl)methoxycarbonylaminomethyl]benzamide is synthesized in accordance with Example 48 of EP 0847992 and used as a control compound (CMDC). Inhibition of cell growth in monolayer for 72 hours of compound treatment is measured in
triplicate experiments and used to derive the IC50 by MTS assay. The results are shown in Table B1.
Table B1
Monolayer Growth ICfin (uM)
Compound H1299 HCT116
CMD1 0.40 0.03
CMD2 0.15 0.01
CMD3 0.58 0.03
CMD4 0.28 0.03
CMD5 0.18 0.03
CMDC 6.8 0.67
The results show that the hydroxamate compounds of the present invention are highly active in inhibition of tumor cell growth. In addition to the above results, it has been observed that the compounds selectively inhibited tumor cells while showing minimal inhibition activities in non-tumorous cells.
The cells treated with the hydroxamate compounds are also tested for the induction of p21 promoter, which is a key mediator of G1 arrest and differentiation. The hydroxamate compounds activate the p21 promoter to a readily detectable level at a concentration within two-fold of their respective IC50 for monolayer cell growth inhibition in H1299. Without being bound by any particular theory, the correlation appears to demonstrate that HDA inhibition leads to transcriptional activation of genes that inhibit tumor cell proliferation.
Example B2
HDA is partially purified from H1299, human non-small cell lung carcinoma cells (obtained from American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, USA). Cells are grown to 70-80% confluence in RPMI media in the presence of 10% FCS, harvested and lysed by sonication. The lysate is centrifuged at 23, 420g for 10-15 min, the supernatant is applied to a Hiload 26/10 High performance Q-sepharose column (Amersham Pharmacia Biotech), and equilibrated with a buffer containing 20 mM Tris
pH8.0, 1 mM EDTA, 10 mM NH4CI2, 1 mM β-Mercaptoethanol, 5% glycerol, 2 μg/mL aprotinin, 1 μg/mL leupeptin, and 400 mM PMSF. Proteins are eluted in 4mL aliquotes with a linear gradient from 0-500 mM NaCI in the above buffer at a flow rate of 2.5 mlJmin. Each preparation of partially purified HDA enzyme is titrated to determine the optimal amount needed to obtain a signal to noise ratio of at least 5 to 1. Generally, 20-30 μl of partially purified HDA (5-10 mg protein/mL) is mixed with 2 μL of compound solution in DMSO in a deep well titer plate (Beckman). The compounds are serially diluted in DMSO to generate stocks at 20-fold of the assay concentrations. Final concentrations of compounds in the assay are 10 μM, 2 μM, 400 nM, 80 nM, and 16 nM with the final percentage of DMSO in each enzyme reaction equaling 0.1%. Each concentration of compound is assayed in duplicate. The substrate used in the reaction is a peptide of amino acid sequence, SGRGKGGKGLGKGGAKRHRKVLRD, corresponding to the twenty-four N-terminal amino acids of human histone H4, biotinylated at the N-terminus and penta-acetylated, at each lysine residue with 3H-acetate. To initiate the reaction, the substrate is diluted in 10 μL of Buffer A (100 mM Tris pH 8.0, 2 mM EDTA), added to the enzyme mixture and collected at the bottom of the deep well plate by centrifugation for 5 minutes at 1500 rpm. Following centrifugation, the mixture is incubated at 37 °C for 1.5 hr. The reaction is stopped by the addition of 20 μL of the Stop Buffer (0.5N HCI, 0.08M Acetic Acid). At this point, the assay proceeds to the robotic extraction phase or is frozen for several days at -80 °C.
The extraction of enzymatically cleaved 3H-acetate groups from the reaction mixture is achieved with the solvent TBME (t-butyl methyl ether) using the Tomtec Quadra 96 workstation. A program is written to add 200 μL of TBME to a 96 "deep well" plate. The workstation is programmed to aspirate 50 μL of air followed by 200 μL of TBME and finally another 25 μL of air, which is dispensed into the each well of the plate. The contents of the deep well were mixed thoroughly by pipetting 160 μL up and down 10 times. Before addition of TBME to the reaction mixture, it is necessary to "pre-wet" the pipette tips with TBME to prevent the solvent from dripping during the transfer to the deep well plate. The organic and aqueous phases in the deep well are separated by centrifugation at 1500 rpm for 5 min. Opti-Phase Supermix liquid scintillation cocktail (200 μL) (Wallac) is added to each well of the 96-well Trilux plate (Wallac). The deep well and Trilux plates are placed back on the workstation programmed to aspirate 25 μL of air into the pipette tips followed by 100 μL of the upper TBME phase and transfer it into the Trilux plate. The solutions are mixed by pipetting and expelling 50 μL, five times, within the same well. The Trilux plate is
covered with clear film and read on a 1450 MicroBeta Trilux liquid scintillation and luminescence counter (Wallac) with a color/chemical quench and dpm correction.
In order to determine the IC50 values, the data are analyzed on a spreadsheet. The analysis requires a correction for the background luminescence that is accomplished by subtracting the dpm values of wells without 3H substrate from the experimental wells. The corrected dpm values along with the concentrations of the compounds are used to calculate IC50 using the user-defined spline function. This function utilizes linear regression techniques between data points to calculate the concentration of compounds that produced 50% inhibition. The results are shown in Table B2.
Table B2
Compound HDA Enzvme Activity IC™ (μM)
CMD1 0.032
CMD2 0.063
CMD3 0.014
CMD4 0.014
CMD5 0.016
CMDC > 10
Example B3
The A549 non-small cell lung human tumor cell line is purchased from the American Type Culture Collection, Rockville, MD. The cell line is free of Mycoplasma contamination (Rapid Detection System by Gen-Probe, Inc., San Diego, CA) and viral contamination (MAP testing by MA BioServices, Inc., Rockville, MD). The cell line is propagated and expanded in RPMI 1640 medium containing 10% heat-inactivated FBS (Life Technologies, Grand Island, NY). Cell expansions for implantation are performed in cell factories (NUNC, purchased from Fisher Scientific, Springfield, NJ). Cells are harvested at 50-90% confluency, washed once with HBSS containing 10% FBS, and suspended in 100% HBSS.
Outbred athymic (nu/nu) female mice ("Hsd:Athymic Nude-nu" from Harlan Sprague Dawley, Indianapolis, IN) are anesthetized with Metofane (Mallinckrodt Veterinary, Inc.,
Mundelein, IL), and 100 μL of the cell suspension containing 1x107 cells is injected subcutaneously into the right axillary (lateral) region of each animal. Tumors are allowed to grow for about 20 days until a volume of -100 mm3 is achieved. At this point, mice bearing tumors with acceptable morphology and size are sorted into groups of eight for the study. The sorting process produces groups balanced with respect to mean and range of tumor size. Antitumor activity is expressed as % T/C, comparing differences in tumor volumes for treatment group (T) to vehicle control group (C). Regressions are calculated using the formula: (1-T/T0) x 100%, where T is the tumor volume for the treatment group at the end of the experiment, and T0 is the tumor volume at the beginning of the experiment.
CMD1 is administered intravenously, once daily 5x week for three weeks, at doses of 10, 25, 50, or 100 mg/kg. The final DMSO concentration is 10%. Each test group has eight mice. Tumors are measured, and individual animal body weights recorded. Table B3 shows the results on the 41st day.
Table B3
Δ MEAN Δ %
DOSE TUMOR VOLUME 1 BODY WEIGHT*2
COMPOUND (mg/kg) (mm3 ± SEM*3) % T/C (% ± SEM*3.
10% DMSO/D5W*4 - 376 ± 55 - +11.9 ± 0.2
CMD1 10 121 + 27 32 + 1.3 + 0.3
CMD1 25 77 ± 32 20 - 0.9 ± 0.3
CMD1 50 57 + 10 15 - 0.4 ± 0.3
CMD1 100 28 ± 25 7 + 0.4 ± 0.3
Note:*1. Difference in mean tumor volume for a group of animals at the end of the experiment minus mean tumor volume at the beginning.
*2. Difference in body weight for a group of animals at the end of the experiment minus mean tumor volume at the beginning.
*3. Standard error of the mean.
*4. 5% dextrose injection, USP.
Example B4
Example B3 repeated except CMD2 is used. Table B4 shows the results.
Table B4
Δ MEAN Δ %
DOSE TUMOR VOLUME BODY WEIGHT
COMPOUND (mg/kg) (mm3 ± SEM) % T/C (% ± SEM)
10% DMSO/D5W - 135 ± 43 - + 6.7 ± 1.1
CMD2 25 37 ± 16 27 - 4.2 ± 2.5
CMD2 50 29 ± 15 21 - 2.9 ± 1.5
Example B5
Example B3 is repeated except the HCT116 colon tumor cell line is used in place of the A549 cell line. The HCT116 cell line is also obtained from American Type Culture Collection, Rockville, MD, and the cell line is free of Mycoplasma contamination and viral contamination. The results are recorded on the 34th day and are shown in Table B5.
Table B5
Δ MEAN Δ %
DOSE TUMOR VOLUME BODY WEIGHT
COMPOUND (mq/kq) (mm3 ± SEM) % T/C (% ± SEM)
10% DMSO/D5W - 759 ± 108 - - 0.4 ± 0.4
CMD1 50*10 186 ± 40 25 - 7.4 ± 0.8
CMD1 100 140 ± 38 18 - 3.2 ± 0.4
Note: *10. Seven mice are tested in this group.
Example B6
Example B4 is repeated except the HCT116 colon tumor cell line is used in place of the A549 cell line. The HCT116 is also obtained from American Type Culture Collection, Rockville, MD, and the cell line is free of Mycoplasma contamination and viral contamination. The results are recorded on the 34th day and are shown in Table B6.
Table B6
Δ MEAN Δ %
DOSE TUMOR VOLUME BODY WEIGHT
COMPOUND (mq/kq) (mm3 ± SEM) % T/C (% ± SEM)
10% DMSO/D5W - 759 ± 108 - - 0.4 ± 0.4
CMD2 10 422 ± 75 56 - 10.2 ± 0.5
CMD2 25 305 ± 47 40 - 7.0 ± 0.2
)
CMD2 50 97 ± 30 13 - 7.3 ± 0.3
CMD2 100 132 ± 30 17 - 9.4 ± 0.4
Example B7
Annexin V binding was used as a marker for the early stages of apoptosis. A549, HCT116 and Normal Dermal Human Fibroblasts (NDHF) cells are treated separately with four compounds (CMD1, CMD2, CMD3 and CMD4) for 24 or 48 hours, stained with annexin V and compared to cells treated similarly with vehicle (DMSO). Cells are examined by fluorescence microscopy. Those undergoing apoptosis exhibit green fluorescent membrane staining. Viability is assessed by the counterstain, propidium iodide. Cells detected by red fluorescence are not viable. A small percentage of A549 and the majority of HCT116 cells exhibit cell surface staining with annexin V after 24 hour exposure to each of the four compounds. After 48 hour treatment, the majority of the A549 and HCT116 stain with annexin V and/or propidium iodide indicating that the compounds induce apoptotic cell death. In contrast, NDHF cells do not show noticeable annexin V staining after 24 hour exposure and limited annexin V staining with CMD3 after 48 hour. These data show that
NDHF cells predominantly underwent non-lethal growth arrest upon compound treatment, consistent with the cell cycle profile.
The staining results demonstrate that the hydroxamate compounds of the present invention cause tumor cells to die by apoptosis, while causing normal fibroblast to predominantly undergo cell cycle arrest, clearly demonstrating the selective efficacy of the present compounds.
Claims (40)
1. A compound of the formula I
wherein
RT is H, halo, or a straight chain C C6 alkyl;
R2 is selected from H, C Cιo alkyl, C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, C - Cg heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, -(CH2)nC(O)R6, -(CH2)nOC(O)R6, amino acyl, HON-C(O)-CH=C(Rι)-aryl-alkyl- and -(CH2)nR7;
R3 and R4 are the same or different and independently H, Cι-C6 alkyl, acyl or acylamino, or R3 and R4 together with the carbon to which they are bound represent C=O, C=S, or C=NR8, or R2 together with the nitrogen to which it is bound and R3 together with the carbon to which it is bound can form a C4 - C9 heterocycloalkyl, a heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring;
R5 is selected from H, CrC6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, acyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aromatic polycycle, non-aromatic polycycle, mixed aryl and non-aryl polycycle, polyheteroaryl, non-aromatic polyheterocycle, and mixed aryl and non-aryl polyheterocycle; n, ni, n2 and n3 are the same or different and independently selected from 0 - 6, when ni is 1-6, each carbon atom can be optionally and independently substituted with R3 and/or R4;
X and Y are the same or different and independently selected from H, halo, C C4 alkyl, NO2, C(O)Rι, ORg, SR9, CN, and NRioRn; R6 is selected from H, CrC6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, OR12, and NRι3Rι4; R7 is selected from OR15, SR15, S(O)R16, SO2Rι7, NRι3Rι4, and NRι2SO2R6; R8 is selected from H, OR15, NRι3R14, CrC6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; R9 is selected from Ci - C4 alkyl and C(O)-alkyl; R10 and Rn are the same or different and independently selected from H, C C4 alkyl, and -C(O)-alkyl; Rι2 is selected from H, Cι-C6 alkyl, C4 - Cg cycloalkyl, C - Cg heterocycloalkyl, C4 - C9 heterocycloalkylalkyl, aryl, mixed aryl and non-aryl polycycle, heteroaryl, arylalkyl, and heteroarylalkyl; Rι3 and R,4 are the same or different and independently selected from H, Cι-C6 alkyl,
C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, amino acyl, or Rι3 and R 4 together with the nitrogen to which they are bound are
C4 - Cg heterocycloalkyl, heteroaryl, polyheteroaryl, non-aromatic polyheterocycle or mixed aryl and non-aryl polyheterocycle; R15 is selected from H, Ci-Ce alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZR12; Rie is selected from C.-C6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, polyheteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZRι2; R17 is selected from CrC6 alkyl, C4 - C9 cycloalkyl, C - Cg heterocycloalkyl, aryl, aromatic polycycle, heteroaryl, arylalkyl, heteroarylalkyl, polyheteroaryl and NR13Rι ; m is an integer selected from 0 to 6; and Z is selected from O, NRi3, S and S(O); or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1 wherein each of Ri, X, Y, R3, and R4 is H.
3. A compound of claim 2 wherein one of n2 and n3 is zero and the other is 1.
4. A compound of claim 3 wherein R2 is H or -CH2-CH2-OH.
5. A compound of claim 1 of the formula la wherein n4 is 0-3,
R2 is selected from H, CrC6 alkyl, C4 - Cg cycloalkyl, C4 - C9 heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, -(CH2)nC(O)R6, amino acyl and -(CH2)nR7; R5' is heteroaryl, heteroarylalkyl, an aromatic polycycle, a non-aromatic polycycle, a mixed aryl and non-aryl polycycle, polyheteroaryl, or a mixed aryl and non-aryl polyheterocycle, or a pharmaceutically acceptable salt thereof.
6. A compound of claim 1 of the formula la
wherein n is 0-3,
R2 is selected from H, CrC6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, -(CH2)nC(O)R6, amino acyl and -(CH2)nR7; R5' is aryl, arylalkyl, an aromatic polycycle, a non-aromatic polycycle or a mixed aryl and non-aryl polycycle, or a pharmaceutically acceptable salt thereof.
7. A compound of claim 6 wherein R5' is aryl or arylalkyl.
8. A compound of claim 7 wherein R5' is p-fluorophenyl, p-chlorophenyl, p-O-C C4- alkylphenyl, p-d-C4-alkylphenyl, benzyl, ortho, meta or para-fluorobenzyl, ortho, meta or para-chlorobenzyl, or ortho, meta or para - mono, di or tri-O-CrC4-alkylbenzyl.
9. A compound of claim 1 of the formula lb
wherein
R2' is selected from H, CrC6 alkyl, C -C6 cycloalkyl, cycloalkylalkyl, -(CH2)2-4OR2ι where R2ι is H, methyl, ethyl, propyl, or isopropyl, and
R5" is unsubstituted or substituted 1 rY-indol-3-yl, benzofuran-3-yl or quinolin-3-yl, or a pharmaceutically acceptable salt thereof.
10. A compound of claim 9 wherein R5" is substituted 1 H-indol-3-yl or substituted benzofuran-3-yl.
11. A compound of claim 1 of the formula lc
wherein the ring containing Zi is aromatic or non-aromatic which non-aromatic rings are saturated or unsaturated, R18 is H, halo, d-C6alkyl, C3-C7cycloalkyl, aryl, or heteroaryl; R20 is H, Cι-C6alkyl, d-Cealkyl-Or-Cgcycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, acyl or sulfonyl;
Ai is 1, 2 or 3 substituents which are independently H, Cι-C-6alkyl, -OR19, halo, alkylamino, aminoalkyl, halo, or heteroarylalkyl;
R2 is selected from H, Cι-C6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, -(CH2)nC(O)R6, amino acyl and -(CH2)nR7;
R19 is selected from H, d-C6alkyl, C4-C9cycIoalkyl, C4-Cgheterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; v is O, 1 or 2, p is 0-3, and q is 1 -5 and r is 0 or q is 0 and r is 1-5, or a pharmaceutically acceptable salt thereof.
12. A compound of claim 11 wherein Z, is N-R20.
13. A compound of claim 11 wherein R2 is H or -CH2-CH2-OH and the sum of q and r is 1.
14. A compound of claim 1 of the formula Id
wherein
R18 is H, halo, CrC6alkyl, C3-C7cycloalkyl, unsubstituted phenyl, substituted phenyl, or heteroaryl, R20 is H, d-C6alkyl, Cι-C6alkyl-C3-C9cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, acyl or sulfonyl;
Ai is 1 , 2 or 3 substituents which are independently H, Cι-C-6alkyl, -OR19, or halo,
Rι9 is selected from H, d-C6alkyl, C4-C9cycloalkyl, C4-C9heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and -(CH2CH=CH(CH3)(CH2))ι-3H; p is 0-3, and q is 1 -5 and r is 0 or q is 0 and r is 1-5, or a pharmaceutically acceptable salt thereof.
15. A compound of claim 14 wherein R2 is H or -CH2-CH2-OH and the sum of q and r is 1.
16. A compound of claim 11 of the formula le
or a pharmaceutically acceptable salt thereof.
17. A compound of claim 16 wherein Rι8 is H, fluoro, chloro, bromo, Cι-C alkyl, C3- dcycloalkyl, phenyl or heteroaryl.
18. A compound of claim 16 wherein R2 is H, or -(CH2)pCH2OH and wherein p is 1-3.
19. A compound of claim 18 wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1 -3.
20. A compound of claim 16 wherein Rι8 is H, methyl, ethyl, t-butyl, trifluoromethyl, cyclohexyl, phenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 2-furanyl, 2-thiophenyl, or 2-, 3- or 4-pyridyl.
21. A compound of claim 20 wherein R2 is H, or -(CH2)pCH2OH.
22. A compound of claim 21 wherein p is 1-3.
23. A compound of claim 22 wherein Ri is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1-3.
24. A compound of claim 23 wherein R2 is H or -CH2-CH2-OH and the sum of q and r is 1.
25. A compound of claim 16 wherein R20 is H or d-C6alkyl.
26. A compound of claim 16 seleoted from the group consisting of N-hydroxy-3-[4-[[(2- hydroxyethyl)[2-(1 H-indol-3-yl)ethylj-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3- [4-[[[2-(1 H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4- [[[2-(2-methyl-1 rV-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof.
27. A compound of claim 26 which is N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indol-3- yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof.
28. A compound of claim 1 of the formula If
or a pharmaceutically acceptable salt thereof.
29. A compound of claim 28 wherein R2 is H or -(CH2)pCH2OH and p is 1 -3.
30. A compound of claim 29 wherein R, is H and X and Y are each H, and wherein q is 1-3 and r is 0 or wherein q is 0 and r is 1 -3.
31. A compound of claim 30 wherein R2 is H or -CH2-CH2-OH and the sum of q and r is 1.
32. A compound of claim 28 which is N-hydroxy-3-[4-[[[2-(benzofur-3-yl)-ethyI]- amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof.
33. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of formula I
wherein
Ri is H, halo, or a straight chain d-Ce alkyl;
R2 is selected from H, d-C10 alkyl, C4 - Cg cycloalkyl, C4 - C9 heterocycloalkyl, C - C9 heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, -(CH2)nC(O)R6, -(CH2)nOC(O)R6, amino acyl, HON-C(O)-CH=C(Rι)-aryl-alkyl- and -(CH2)nR7;
R3 and R4 are the same or different and independently H, d-C6 alkyl, acyl or acylamino, or R3 and R4 together with the carbon to which they are bound represent C=O, C=S, or C=NR8, or R2 together with the nitrogen to which it is bound and R3 together with the carbon to which it is bound can form a C4 - C9 heterocycloalkyl, a heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring; R5 is selected from H, d-C6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, acyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aromatic polycycle, non-aromatic polycycle, mixed aryl and non-aryl polycycle, polyheteroaryl, non-aromatic polyheterocycle, and mixed aryl and non-aryl polyheterocycle; n, ni, n2 and n3 are the same or different and independently selected from 0 - 6, when n, is 1-6, each carbon atom can be optionally and independently substituted with R3 and/or R4; X and Y are the same or different and independently selected from H, halo, d-C4 alkyl,
NO2, C(O)Rι, OR9, SR9, CN, and NRι0Rn; R6 is selected from H, Ci-Ce alkyl, C - C9 cycloalkyl, C - Cg heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, OR12, and NR13R14; R7 is selected from ORι5, SRι5, S(O)Rι6, SO2Rι7, NR13Rι4, and NRι2SO2R6; R8 is selected from H, ORι5, NRι3Rι4, CrC6 alkyl, C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; R9 is selected from Ci - C4 alkyl and C(O)-alkyl; Rio and Rn are the same or different and independently selected from H, d-C4 alkyl, and -C(O)-alkyl; R12 is selected from H, Ci-Ce alkyl, C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, C4 - C9 heterocycloalkylalkyl, aryl, mixed aryl and non-aryl polycycle, heteroaryl, arylalkyl, and heteroarylalkyl; Rι3 and Ru are the same or different and independently selected from H, Ci-Ce alkyl,
C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, amino acyl, or R 3 and Ri together with the nitrogen to which they are bound are
C4 - C9 heterocycloalkyl, heteroaryl, polyheteroaryl, non-aromatic polyheterocycle or mixed aryl and non-aryl polyheterocycle; Ri5 is selected from H, d-C6 alkyl, C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZRι2; Rιe is selected from d-C6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, polyheteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZRι2; Rι7 is selected from Cι-C6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, aromatic polycycle, heteroaryl, arylalkyl, heteroarylalkyl, polyheteroaryl and NRι3Rι4; m is an integer selected from 0 to 6; and Z is selected from O, NR13, S and S(O); pharmaceutically acceptable salt thereof.
34. A pharmaceutical composition of claim 33 wherein the compound of formula I is selected from the group consisting of N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indol-3- yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]- amino]methyl]phenyl]-2E-2-propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1 -/-indol-3-yl)- ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof.
35. A pharmaceutical composition of claim 34 wherein the compound of formula I is N- hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide, or a pharmaceutically acceptable salt thereof.
36. A pharmaceutical composition of claim 33 wherein the compound of formula I is N- hydroxy-3-[4-[[[2-(benzofur-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof.
37. A method for treating a proliferative disorder in a mammal which comprises administering to said mammal a compound of the formula I
wherein
Ri is H, halo, or a straight chain Ci-Ce alkyl;
R2 is selected from H, C1-C10 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, C4 - C9 heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl,
-(CH2)nC(O)R6, -(CH2)nOC(O)R6, amino acyl, HON-C(O)-CH=C(Rι)-aryl-alkyl- and
-(CH2)nRr; R3 and R4 are the same or different and independently H, Ci-Ce alkyl, acyl or acylamino. or R3 and R together with the carbon to which they are bound represent C=O, C=S, or C=NR8, or R2 together with the nitrogen to which it is bound and R3 together with the carbon to which it is bound can form a C4 - C9 heterocycloalkyl, a heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring; R5 is selected from H, Ci-Ce alkyl, C4 - Cg cycloalkyl, C - C9 heterocycloalkyl, acyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aromatic polycycle, non-aromatic polycycle, mixed aryl and non-aryl polycycle, polyheteroaryl, non-aromatic polyheterocycle, and mixed aryl and non-aryl polyheterocycle; n, ni, n2 and n3 are the same or different and independently selected from 0 - 6, when ni is 1-6, each carbon atom can be optionally and independently substituted with R3 and/or R4; X and Y are the same or different and independently selected from H, halo, d-C alkyl,
NO2, C(O)R1f OR9, SR9, CN, and NRι0Rn; R6 is selected from H, C C6 alkyl, C4 - C9 cycloalkyl, C4 - Cg heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, ORι2, and NRι3Rι4; R7 is selected from OR15, SR15, S(O)Rι6, SO2Rι7, NRι3Rι4, and NRι2SO2R6; R8 is selected from H, ORι5, NRι3Ri4, Ci-Ce alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; R9 is selected from Ci - C4 alkyl and C(O)-alkyl; Rio and Rn are the same or different and independently selected from H, CrC alkyl, and -C(O)-alkyl; R12 is selected from H, Cι-C6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, C4 - C9 heterocycloalkylalkyl, aryl, mixed aryl and non-aryl polycycle, heteroaryl, arylalkyl, and heteroarylalkyl; Rι3 and R 4 are the same or different and independently selected from H, Ci-Ce alkyl,
C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, amino acyl, or R 3 and Rι4 together with the nitrogen to which they are bound are
C4 - C9 heterocycloalkyl, heteroaryl, polyheteroaryl, non-aromatic polyheterocycle or mixed aryl and non-aryl polyheterocycle; R15 is selected from H, Cι-C6 alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZR12; Rie is selected from Cι-C6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, polyheteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZRι2; Rι7 is selected from Ci-Ce alkyl, C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, aryl, aromatic polycycle, heteroaryl, arylalkyl, heteroarylalkyl, polyheteroaryl and Rι3R 4; m is an integer selected from 0 to 6; and Z is selected from O, NRι3, S and S(O); or a pharmaceutically acceptable salt thereof.
38. A method of claim 37 wherein the compound of formula I is selected from the group consisting of N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indol-3-yl)ethyl]-amino]methyl]phenyl]- 2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]methyl]phenyl]- 2E-2-propenamide, or a pharmaceutically acceptable salt thereof.
39. A method for regulating p21 promoter which comprises introducing a compound of the formula I
wherein
Ri is H, halo, or a straight chain Ci-Ce alkyl;
R2 is selected from H, C1-C10 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, C - C9 heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, -(CH2)nC(O)R6, -(CH2)nOC(O)R6, amino acyl, HON-C(O)-CH=C(Rι)-aryl-alkyl- and -(CH2)nR7;
R3 and R4 are the same or different and independently H, Ci-Ce alkyl, acyl or acylamino, or R3 and R4 together with the carbon to which they are bound represent C=O, C=S, or C=NR8, or R2 together with the nitrogen to which it is bound and R3 together with the carbon to which it is bound can form a C4 - C9 heterocycloalkyl, a heteroaryl, a polyheteroaryl, a non-aromatic polyheterocycle, or a mixed aryl and non-aryl polyheterocycle ring; R5 is selected from H, Ci-Ce alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, acyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aromatic polycycle, non-aromatic polycycle, mixed aryl and non-aryl polycycle, polyheteroaryl, non-aromatic polyheterocycle, and mixed aryl and non-aryl polyheterocycle; n, n , n2 and n3 are the same or different and independently selected from 0 - 6, when ni is 1 -6, each carbon atom can be optionally and independently substituted with R3 and/or R4; X and Y are the same or different and independently selected from H, halo, Cι-C alkyl,
NO2, C(O)Rι, OR9, SR9, CN, and NRι0Rn; R6 is selected from H, d-C6 alkyl, C4 - C9 cycloalkyl, C4 - Cg heterocycloalkyl, cycloalkylalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, ORι2, and NRι3Rι4; R7 is selected from OR15, SRι5, S(O)Rι6, SO2Rι7, NRι3Rι4, and NR12SO2R6; R8 is selected from H, ORι5, NRι3Rι4, Cι-C6 alkyl, C4 - C9 cycloalkyl, C - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; R9 is selected from Ci - C4 alkyl and C(O)-alkyl; Rio and Rn are the same or different and independently selected from H, Cι-C4 alkyl, and -C(O)-alkyl; Rι2 is selected from H, Ci-Ce alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, C4 - C9 heterocycloalkylalkyl, aryl, mixed aryl and non-aryl polycycle, heteroaryl, arylalkyl, and heteroarylalkyl; Rι3 and Rι4 are the same or different and independently selected from H, CrC6 alkyl,
C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, amino acyl, or Rι3 and R,4 together with the nitrogen to which they are bound are
C4 - C9 heterocycloalkyl, heteroaryl, polyheteroaryl, non-aromatic polyheterocycle or mixed aryl and non-aryl polyheterocycle; R15 is selected from H, Ci-Ce alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZRι2; R16 is selected from Ci-Ce alkyl, C - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, heteroaryl, polyheteroaryl, arylalkyl, heteroarylalkyl and (CH2)mZR12; Rι7 is selected from C C6 alkyl, C4 - C9 cycloalkyl, C4 - C9 heterocycloalkyl, aryl, aromatic polycycle, heteroaryl, arylalkyl, heteroarylalkyl, polyheteroaryl and NRι3Rι ; m is an integer selected from 0 to 6; and Z is selected from O, NRi3, S and S(O); pharmaceutically acceptable salt thereof, into the environment of a mammalian cell.
40. A method of claim 39 wherein the compound of formula I is selected from the group consisting of N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H-indol-3-yl)ethyl]-amino]methyl]phenyl]- 2E-2-propenamide, N-hydroxy-3-[4-[[[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2- propenamide and N-hydroxy-3-[4-[[[2-(2-methyl-1 H- indol-3-yl)-ethyl]-amino]methyl]phenyl]- 2E-2-propenamide, or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22994300P | 2000-09-01 | 2000-09-01 | |
US60/229,943 | 2000-09-01 | ||
US29223201P | 2001-05-18 | 2001-05-18 | |
US60/292,232 | 2001-05-18 | ||
PCT/EP2001/010037 WO2002022577A2 (en) | 2000-09-01 | 2001-08-30 | Hydroxamate derivatives useful as deacetylase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2001282129A1 true AU2001282129A1 (en) | 2002-06-13 |
AU2001282129B2 AU2001282129B2 (en) | 2005-08-25 |
Family
ID=26923760
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001282129A Ceased AU2001282129B2 (en) | 2000-09-01 | 2001-08-30 | Hydroxamate derivatives useful as deacetylase inhibitors |
AU8212901A Pending AU8212901A (en) | 2000-09-01 | 2001-08-30 | Deacetylase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU8212901A Pending AU8212901A (en) | 2000-09-01 | 2001-08-30 | Deacetylase inhibitors |
Country Status (36)
Country | Link |
---|---|
US (5) | US6552065B2 (en) |
EP (2) | EP1318980B1 (en) |
JP (1) | JP4012819B2 (en) |
KR (1) | KR100585484B1 (en) |
CN (1) | CN1300110C (en) |
AR (1) | AR035057A1 (en) |
AT (1) | ATE376999T1 (en) |
AU (2) | AU2001282129B2 (en) |
BE (1) | BE2015C062I2 (en) |
BR (1) | BRPI0113669B8 (en) |
CA (1) | CA2420899C (en) |
CY (2) | CY1107839T1 (en) |
CZ (1) | CZ302707B6 (en) |
DE (1) | DE60131179T2 (en) |
DK (1) | DK1318980T3 (en) |
EC (1) | ECSP034492A (en) |
ES (1) | ES2292610T3 (en) |
FR (1) | FR15C0086I2 (en) |
HK (1) | HK1057746A1 (en) |
HU (2) | HU229796B1 (en) |
IL (2) | IL154574A0 (en) |
LU (1) | LU92890I2 (en) |
MX (1) | MXPA03001832A (en) |
MY (1) | MY136892A (en) |
NL (1) | NL300778I2 (en) |
NO (2) | NO324942B1 (en) |
NZ (1) | NZ524365A (en) |
PE (1) | PE20020354A1 (en) |
PL (1) | PL221738B1 (en) |
PT (1) | PT1318980E (en) |
RU (1) | RU2302408C3 (en) |
SI (1) | SI1318980T1 (en) |
SK (1) | SK287609B6 (en) |
TW (1) | TWI286544B (en) |
WO (1) | WO2002022577A2 (en) |
ZA (1) | ZA200301423B (en) |
Families Citing this family (428)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US6822267B1 (en) * | 1997-08-20 | 2004-11-23 | Advantest Corporation | Signal transmission circuit, CMOS semiconductor device, and circuit board |
EP1233958B1 (en) | 1999-11-23 | 2011-06-29 | MethylGene Inc. | Inhibitors of histone deacetylase |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
PE20020354A1 (en) * | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
CA2423868C (en) | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
US7312247B2 (en) * | 2001-03-27 | 2007-12-25 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
EP2269609A3 (en) | 2001-10-16 | 2012-07-11 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
ATE352319T1 (en) * | 2001-11-06 | 2007-02-15 | Novartis Pharma Gmbh | COMBINATION CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR |
US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
BR0308250A (en) | 2002-03-04 | 2005-01-11 | Aton Pharma Inc | Terminal Differentiation Induction Methods |
CA2479906C (en) | 2002-04-03 | 2011-02-08 | Topotarget Uk Limited | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
AU2003219595A1 (en) | 2002-04-11 | 2003-10-27 | In2Gen Co., Ltd. | Alpha,Beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS |
AU2003226408B2 (en) * | 2002-04-15 | 2007-06-14 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
SG162616A1 (en) * | 2002-06-10 | 2010-07-29 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
JP4804004B2 (en) * | 2002-08-20 | 2011-10-26 | アステラス製薬株式会社 | Articular cartilage extracellular matrix degradation inhibitor |
EP1553948B1 (en) * | 2002-09-13 | 2011-08-24 | Virginia Commonwealth University | Combination of imatnib and a histone deacetylase inhibitor for the treatment of leukemia |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20060223826A1 (en) * | 2002-11-19 | 2006-10-05 | Takeda Pharmaceutical Company Limited Intellectual Property Department | Indole derivatives as somatostatin agonists or antagonists |
AU2003296310A1 (en) | 2002-12-06 | 2004-06-30 | University Of South Florida | Histone deacetylase inhibitor enhancement of trail-induced apoptosis |
TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
JP4612621B2 (en) | 2003-01-17 | 2011-01-12 | トポターゲット ユーケー リミテッド | Carbamate compounds containing ester or ketone linkages as HDAC inhibitors |
AU2003900587A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
AU2003900608A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
JP4790594B2 (en) | 2003-02-25 | 2011-10-12 | トポターゲット ユーケー リミテッド | Hydroxamic acid compounds containing bicyclic heteroaryl groups as HDAC inhibitors |
JP2006520796A (en) * | 2003-03-17 | 2006-09-14 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
BRPI0410648A (en) * | 2003-05-21 | 2006-07-04 | Novartis Ag | combination of histone deacetylase inhibitors with chemotherapeutic agents |
WO2005011598A2 (en) * | 2003-07-31 | 2005-02-10 | University Of South Florida | Leukemia treatment method and composition |
WO2005013958A1 (en) * | 2003-08-07 | 2005-02-17 | Novartis Ag | Histone deacetylase inhibitors as immunosuppressants |
CA2533861A1 (en) | 2003-08-08 | 2005-02-17 | Novartis Ag | Combinations comprising staurosporines |
PL1663194T3 (en) | 2003-08-26 | 2011-01-31 | Merck Hdac Res Llc | Use of SAHA for treating mesothelioma |
US20070190022A1 (en) | 2003-08-29 | 2007-08-16 | Bacopoulos Nicholas G | Combination methods of treating cancer |
CN100455564C (en) * | 2003-09-12 | 2009-01-28 | 深圳微芯生物科技有限责任公司 | Histone de-acetylase inhibitor, preparation and application of pharmaceutical preparations of the same |
CN1852737A (en) * | 2003-09-18 | 2006-10-25 | 诺瓦提斯公司 | Combination of a histone deacetylase inhibitor with a death receptor ligand |
EP1673349B1 (en) * | 2003-09-22 | 2010-06-30 | S*Bio Pte Ltd | Benzimidazole derivatives: preparation and pharmaceutical applications |
BRPI0414581C1 (en) | 2003-09-22 | 2021-05-25 | Mei Pharma Inc | compound, pharmaceutical composition comprising said compound and use of said compound |
JP2007505938A (en) * | 2003-09-23 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Combination of VEGF receptor inhibitor and chemotherapeutic agent |
TW200524575A (en) * | 2003-10-27 | 2005-08-01 | S Bio Pte Ltd | Biaryl linked hydroxamates: preparation and pharmaceutical applications |
JP5107579B2 (en) * | 2003-12-02 | 2012-12-26 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | Zn2 + chelate motif tethered short chain fatty acids as a novel class of histone deacetylase inhibitors |
EP1541549A1 (en) * | 2003-12-12 | 2005-06-15 | Exonhit Therapeutics S.A. | Tricyclic hydroxamate and benzaminde derivatives, compositions and methods |
WO2005065681A1 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer |
US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20050197336A1 (en) * | 2004-03-08 | 2005-09-08 | Miikana Therapeutics Corporation | Inhibitors of histone deacetylase |
US7345043B2 (en) * | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
NZ549925A (en) | 2004-04-07 | 2010-08-27 | Novartis Ag | Inhibitors of IAP |
US7507858B2 (en) * | 2004-07-19 | 2009-03-24 | Merck & Co., Inc. | Histone deacetylase inhibitors |
JP4946861B2 (en) * | 2004-08-09 | 2012-06-06 | アステラス製薬株式会社 | Hydroxamide compound having inhibitory activity of histone deacetylase (HDAC) |
ITMI20041869A1 (en) | 2004-10-01 | 2005-01-01 | Dac Srl | NEW INHIBITORS OF DEACETYLASE HISTONS |
US8242175B2 (en) | 2004-10-01 | 2012-08-14 | Dac S.R.L. | Class of histone deacetylase inhibitors |
US20070021612A1 (en) * | 2004-11-04 | 2007-01-25 | University Of Notre Dame Du Lac | Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof |
US7235688B1 (en) | 2004-11-04 | 2007-06-26 | University Of Notre Dame Du Lac | Process for preparing histone deacetylase inhibitors and intermediates thereof |
EP1824831A2 (en) * | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2006088949A1 (en) | 2005-02-14 | 2006-08-24 | Miikana Therapeutics, Inc. | Fused heterocyclic compounds useful as inhibitors of histone deacetylase |
US7666880B2 (en) | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
EP2491926B1 (en) | 2005-03-22 | 2018-05-09 | President and Fellows of Harvard College | Treatment of protein degradation disorders |
GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
JP2008540574A (en) * | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
TWI365068B (en) | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
BRPI0613429A2 (en) | 2005-07-14 | 2009-02-10 | Takeda San Diego Inc | histone deacetylase inhibitors |
WO2007016532A2 (en) * | 2005-08-02 | 2007-02-08 | Novartis Ag | Mutations and polymorphisms of hdac4 |
PL1912640T3 (en) | 2005-08-03 | 2015-11-30 | Novartis Ag | Use of the hdac inhibitor panobinostat for the treatment of myeloma |
BRPI0614903A2 (en) * | 2005-08-10 | 2011-04-19 | Novartis Ag | method of using deacetylase inhibitors |
EP1915154A2 (en) * | 2005-08-11 | 2008-04-30 | Novartis AG | Combination of organic compounds |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
US20070155730A1 (en) * | 2005-08-26 | 2007-07-05 | Methylgene, Inc. | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase |
WO2007030454A2 (en) * | 2005-09-07 | 2007-03-15 | Novartis Ag | Mutations and polymorphisms of hdac9 |
WO2007030455A2 (en) * | 2005-09-07 | 2007-03-15 | Novartis Ag | Mutations and polymorphisms of hdac10 |
WO2007038073A2 (en) * | 2005-09-22 | 2007-04-05 | Novartis Ag | Mutations and polymorphisms of hdac11 |
WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
WO2007047998A2 (en) * | 2005-10-21 | 2007-04-26 | Novartis Ag | Mutations and polymorphisms of hdac2 |
BRPI0617806A2 (en) | 2005-10-24 | 2011-08-09 | Novartis Ag | combination of histone deacetylase inhibitors with radiation |
EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
WO2007053502A2 (en) * | 2005-11-01 | 2007-05-10 | Novartis Ag | Mutations and polymorphisms of hdac5 |
WO2007058992A2 (en) * | 2005-11-14 | 2007-05-24 | Novartis Ag | Mutations and polymorphisms of hdac6 |
US9006224B2 (en) | 2005-11-21 | 2015-04-14 | Novartis Ag | Neuroendocrine tumor treatment |
US20070207950A1 (en) * | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
WO2007084390A2 (en) * | 2006-01-13 | 2007-07-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
RU2008135979A (en) * | 2006-02-07 | 2010-03-20 | Астеллас Фарма Инк. (Jp) | HYDROXYACRYLAMIDE COMPOUNDS |
CA2642273C (en) | 2006-02-14 | 2016-09-20 | President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
EP2004163B1 (en) | 2006-04-05 | 2014-09-17 | Novartis Pharma AG | Combination of everolimus and vinorelbine |
RU2452492C2 (en) | 2006-04-05 | 2012-06-10 | Новартис Аг | COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER |
PL2450437T3 (en) | 2006-04-14 | 2017-12-29 | Cell Signaling Technology Inc | Gene defects and mutant ALK kinase in human solid tumors |
US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
CA2650520A1 (en) | 2006-04-24 | 2008-01-31 | Gloucester Pharmaceuticals | Treatment of ras-expressing tumors |
US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
NZ572299A (en) | 2006-05-09 | 2010-07-30 | Novartis Ag | Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof |
WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
PL2032531T3 (en) * | 2006-06-12 | 2016-07-29 | Novartis Ag | Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
WO2007146716A2 (en) * | 2006-06-12 | 2007-12-21 | Novartis Ag | Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
UA95289C2 (en) * | 2006-06-12 | 2011-07-25 | Новартис Аг | Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
US7989639B2 (en) * | 2006-06-12 | 2011-08-02 | Novartis Ag | Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
RU2448090C2 (en) * | 2006-06-12 | 2012-04-20 | Новартис Аг | Method of producing n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials for said method |
WO2008002862A1 (en) * | 2006-06-26 | 2008-01-03 | Novartis Ag | Organic compounds |
AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
ES2561835T3 (en) | 2006-09-20 | 2016-03-01 | Mei Pharma, Inc. | Imidazo [1,2-a] pyridine hydroxamate compounds that are histone deacetylase inhibitors |
EP2079304A4 (en) * | 2006-09-28 | 2010-01-06 | Merck & Co Inc | Amine base salts of saha and polymorphs thereof |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
WO2008053131A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
US20080242648A1 (en) * | 2006-11-10 | 2008-10-02 | Syndax Pharmaceuticals, Inc., A California Corporation | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
MX2009005946A (en) * | 2006-12-04 | 2009-06-17 | Novartis Ag | Combination. |
CN101583599A (en) * | 2006-12-15 | 2009-11-18 | 安斯泰来制药有限公司 | N-hydroxyacrylamide compounds |
EP2117598A2 (en) * | 2007-01-10 | 2009-11-18 | Novartis AG | Formulations of deacetylase inhibitors |
CA2676422C (en) * | 2007-02-06 | 2018-10-16 | Lixte Biotechnology Holdings, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
EP2120900A2 (en) | 2007-02-15 | 2009-11-25 | Novartis AG | Combination of lbh589 with other therapeutic agents for treating cancer |
WO2008123395A1 (en) | 2007-03-28 | 2008-10-16 | Santen Pharmaceutical Co., Ltd. | Ocular hypotensive agent comprising compound capable of inhibiting histone deacetylase as active ingredient |
TWI539947B (en) | 2007-04-09 | 2016-07-01 | 米希爾金尼公司 | Inhibitors of histone deacetylase |
JP2010526149A (en) * | 2007-05-04 | 2010-07-29 | ノバルティス アーゲー | Use of HDAC inhibitors for the treatment of gastrointestinal cancer |
CN101677995A (en) * | 2007-05-11 | 2010-03-24 | 诺瓦提斯公司 | Use of hdac inhibitors for the treatment of melanoma |
CA2687274A1 (en) * | 2007-05-30 | 2008-12-11 | Novartis Ag | Use of hdac inhibitors for the treatment of bone destruction |
US7737175B2 (en) | 2007-06-01 | 2010-06-15 | Duke University | Methods and compositions for regulating HDAC4 activity |
CA2718472A1 (en) * | 2007-08-03 | 2009-02-12 | Lixte Biotechnology, Inc. | Use of phosphatases to treat neuroblastomas and medulloblastomas |
CL2008002786A1 (en) * | 2007-09-20 | 2009-05-15 | Novartis Ag | Pharmaceutically acceptable cake, formed by lyophilization, comprising: n-hydroxy-3- [4 - [[[2- (2-methyl-1h-indol-3-yl] -ethyl] -amino] -methyl] -phenyl] -2e-2-propenamide or a salt, a selected pH regulator of lactate or lactic acid, phosphate or phosphoric acid or a combination and a bulking agent; manufacturing process. |
EP2200439B1 (en) | 2007-10-01 | 2017-03-22 | Lixte Biotechnology, Inc. | Hdac inhibitors |
WO2009053808A2 (en) * | 2007-10-22 | 2009-04-30 | Orchid Research Laboratories Limited | Histone deacetylase inhibitors |
CN101417967A (en) * | 2007-10-26 | 2009-04-29 | 浙江海正药业股份有限公司 | Histone deacetylase inhibitor, compounds thereof and use thereof |
US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
WO2009067808A1 (en) * | 2007-11-27 | 2009-06-04 | Ottawa Health Research Institute | Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors |
EP2234608A2 (en) | 2007-12-11 | 2010-10-06 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
ITFI20070288A1 (en) | 2007-12-21 | 2009-06-22 | A I L Firenze Sezione Autonoma | INHIBITORS OF ISTONIC DEACETYLASES |
EP2100879A1 (en) * | 2008-03-13 | 2009-09-16 | 4Sc Ag | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
CN102036953B (en) | 2008-03-24 | 2015-05-06 | 诺华股份有限公司 | Arylsulfonamide-based matrix metalloprotease inhibitors |
EA019033B1 (en) | 2008-03-26 | 2013-12-30 | Новартис Аг | Hydroxamate-based inhibitors of deacetylases b |
US20110118309A1 (en) * | 2008-07-18 | 2011-05-19 | Peter Wisdom Atadja | Use of hdac inhibitors for the treatment of hodgkin's disease |
WO2010011296A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
WO2010014220A1 (en) * | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
US8227473B2 (en) * | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
EP2309853A4 (en) * | 2008-08-01 | 2012-04-25 | Lixte Biotechnology Inc | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
GB0903480D0 (en) * | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
KR101168801B1 (en) | 2009-03-27 | 2012-07-25 | 주식회사종근당 | Novel hydroxamate derivatives, method for the preparation thereof, and pharmaceutical composition containing the same |
US7994357B2 (en) | 2009-04-03 | 2011-08-09 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
ES2473792T3 (en) | 2009-04-03 | 2014-07-07 | Naturewise Biotech & Medicals Corporation | Kinematic compounds and derivatives thereof for histone deacetylase inhibition |
US8901337B2 (en) | 2009-07-16 | 2014-12-02 | Royal College Of Surgeons In Ireland | Metal complexes having dual histone deacetylase inhibitory and DNA-binding activity |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
BR112012003262A8 (en) | 2009-08-12 | 2016-05-17 | Novartis Ag | Heterocyclic Hydrazone Compounds and Their Uses to Treat Cancer and Inflammation |
IN2012DN01961A (en) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
JP2013503129A (en) | 2009-08-26 | 2013-01-31 | ノバルティス アーゲー | Tetra-substituted heteroaryl compounds and their use as MDM2 and / or MDM4 modulators |
AR077975A1 (en) | 2009-08-28 | 2011-10-05 | Irm Llc | PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
US20110053925A1 (en) * | 2009-08-28 | 2011-03-03 | Novartis Ag | Hydroxamate-Based Inhibitors of Deacetylases |
CN102596951B (en) | 2009-11-04 | 2015-04-15 | 诺华股份有限公司 | Heterocyclic sulfonamide derivatives useful as MEK inhibitors |
AU2010321533A1 (en) | 2009-11-23 | 2012-05-31 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
US8614239B2 (en) | 2009-12-08 | 2013-12-24 | Novartis Ag | Heterocyclic sulfonamide derivatives |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CU24130B1 (en) | 2009-12-22 | 2015-09-29 | Novartis Ag | ISOQUINOLINONES AND REPLACED QUINAZOLINONES |
US20130040998A1 (en) * | 2010-01-08 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Fluorinated hdac inhibitors and uses thereof |
AU2011205283B2 (en) | 2010-01-13 | 2014-07-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
EP2523664A4 (en) | 2010-01-13 | 2013-06-26 | Tempero Pharmaceuticals Inc | Compounds and methods |
WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
UY33236A (en) | 2010-02-25 | 2011-09-30 | Novartis Ag | DIMERIC INHIBITORS OF THE IAP |
WO2011119995A2 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
US8217079B2 (en) | 2010-03-26 | 2012-07-10 | Italfarmaco Spa | Method for treating Philadelphia-negative myeloproliferative syndromes |
UA112517C2 (en) | 2010-07-06 | 2016-09-26 | Новартіс Аг | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES |
EP2407164A1 (en) | 2010-07-14 | 2012-01-18 | Dublin Institute of Technology Intellectual Property Ltd | Copper II complexes of phenanthroline and their use in cancer treatment |
WO2012025701A1 (en) * | 2010-08-25 | 2012-03-01 | Chroma Therapeutics Ltd. | Alpha, alpha - di substituted glycine ester derivatives and their use as hdac inhibitors |
WO2012025155A1 (en) * | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
JP2013536207A (en) * | 2010-08-27 | 2013-09-19 | ノバルティス アーゲー | Hydroxamate skeleton deacetylase inhibitors |
UY33794A (en) | 2010-12-13 | 2012-07-31 | Novartis Ag | DIMERIC INHIBITORS OF THE IAP |
CN103261186A (en) | 2010-12-13 | 2013-08-21 | 诺瓦提斯公司 | Dimeric IAP inhibitors |
EP2663312B1 (en) | 2011-01-10 | 2017-10-11 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
TW201245115A (en) | 2011-01-24 | 2012-11-16 | Chdi Foundation Inc | Histone deacetylase inhibitors and compositions and methods of use thereof |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
JP6130305B2 (en) | 2011-02-23 | 2017-05-17 | インテリカイン, エルエルシー | Combinations of kinase inhibitors and their use |
MX2013010329A (en) | 2011-03-09 | 2014-03-12 | Sverker Jern | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors. |
JP2014517004A (en) | 2011-06-09 | 2014-07-17 | ノバルティス アーゲー | Heterocyclic sulfonamide derivatives |
JP6200884B2 (en) | 2011-06-14 | 2017-09-20 | ノバルティス アーゲー | Combination of panobinostat and ruxolitinib in the treatment of cancers such as myeloproliferative tumors |
EP2721008B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
SG195067A1 (en) | 2011-06-27 | 2013-12-30 | Novartis Ag | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
MX339302B (en) | 2011-09-15 | 2016-05-19 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase. |
CN108542906A (en) | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | The method for treating proliferative disease |
SG11201401260QA (en) | 2011-11-23 | 2014-07-30 | Novartis Ag | Pharmaceutical formulations |
CN103130673B (en) * | 2011-11-28 | 2017-05-03 | 重庆医药工业研究院有限责任公司 | Preparation method of agomelatine crystal type I |
CN104080787B (en) | 2011-11-29 | 2016-09-14 | 诺华股份有限公司 | Pyrazolo pyrrolidine compound |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
SG11201402237WA (en) | 2011-12-22 | 2014-09-26 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
US20140350014A1 (en) | 2011-12-23 | 2014-11-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
WO2013096049A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
KR20140104047A (en) | 2011-12-23 | 2014-08-27 | 노파르티스 아게 | Compounds for inhibiting the interaction of bcl2 with binding partners |
US20140357633A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
US20140357666A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EP2797875A4 (en) * | 2011-12-29 | 2015-09-02 | Pharmacyclics Inc | Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8 |
EP3608317A1 (en) | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
UY34591A (en) | 2012-01-26 | 2013-09-02 | Novartis Ag | IMIDAZOPIRROLIDINONA COMPOUNDS |
TWI573792B (en) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | Novel therapeutic agents |
ES2894830T3 (en) | 2012-04-03 | 2022-02-16 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
CN104302634B (en) | 2012-05-15 | 2017-02-08 | 诺华股份有限公司 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
AU2013261128B2 (en) | 2012-05-15 | 2015-11-12 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
AU2013261129B2 (en) | 2012-05-15 | 2016-05-12 | Novartis Ag | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
PE20210667A1 (en) | 2012-05-15 | 2021-04-05 | Novartis Ag | BENZAMIDE DERIVATIVES FOR INHIBITION OF ABL1, ABL2 AND BCR-ABL1 ACTIVITY |
CN104321325B (en) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | Pyrrolopyrrole alkanone compound |
US9789193B2 (en) | 2012-06-15 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
TW201408628A (en) | 2012-07-16 | 2014-03-01 | Chdi Foundation Inc | Histone deacetylase inhibitors and compositions and methods of use thereof |
WO2014025395A1 (en) | 2012-08-06 | 2014-02-13 | Duke University | Compounds and methods for targeting hsp90 |
CA2885969C (en) | 2012-10-02 | 2021-04-06 | Epitherapeutics Aps | Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases |
US20150258068A1 (en) | 2012-10-30 | 2015-09-17 | Mei Pharma, Inc. | Combination therapies |
CN105377288B (en) | 2012-11-05 | 2019-11-15 | 达纳-法伯癌症研究所股份有限公司 | The composition of XBP1, CD138 and CS1 peptide prepares the purposes of drug |
EP2916834A1 (en) | 2012-11-08 | 2015-09-16 | Novartis AG | Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
TW201422625A (en) | 2012-11-26 | 2014-06-16 | Novartis Ag | Solid form of dihydro-pyrido-oxazine derivative |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
US9650339B2 (en) | 2013-02-27 | 2017-05-16 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
AU2014251038A1 (en) | 2013-04-08 | 2015-11-26 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
CN105209036B (en) | 2013-04-09 | 2018-10-26 | 莱克斯特生物技术公司 | The preparation of oxa-bicyclo heptane and oxabicyclo heptene |
KR101645379B1 (en) | 2013-04-29 | 2016-08-03 | 주식회사 종근당 | Novel compounds for selective histone deacetylase inhibitor, and the pharmaceutical composition comprising thereof |
US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
UY35675A (en) | 2013-07-24 | 2015-02-27 | Novartis Ag | SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA |
WO2015013581A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
SG11201600028YA (en) | 2013-09-22 | 2016-02-26 | Calitor Sciences Llc | Substituted aminopyrimidine compounds and methods of use |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
CN103467359B (en) * | 2013-09-27 | 2015-04-22 | 山东大学 | Cinnamon amides histone deacetylase inhibitor with benzpyrole and preparation method and application of same |
TW201605450A (en) | 2013-12-03 | 2016-02-16 | 諾華公司 | Combination of Mdm2 inhibitor and BRAF inhibitor and their use |
CN103664734B (en) * | 2013-12-10 | 2015-09-23 | 广州康缔安生物科技有限公司 | Heterocycle hydroximic acid compound and medicinal compositions thereof and application |
TR201900057T4 (en) | 2013-12-12 | 2019-01-21 | Chong Kun Dang Pharmaceutical Corp | New azaindole derivatives and pharmaceutical compositions containing them as selective histone deacetylase (HDAC) inhibitors. |
KR101685639B1 (en) | 2014-01-03 | 2016-12-12 | 주식회사 종근당 | Indole Derivatives Compound, and the pharmaceutical composition comprising the same |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
CN106661039B (en) | 2014-02-28 | 2019-09-13 | 林伯士拉克许米公司 | 2 (TYK2) inhibitor of tyrosine protein matter kinases and its purposes |
WO2015148714A1 (en) | 2014-03-25 | 2015-10-01 | Duke University | Heat shock protein 70 (hsp-70) receptor ligands |
CA2943979A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
JP2017512804A (en) | 2014-03-31 | 2017-05-25 | ギリアード サイエンシーズ, インコーポレイテッド | Inhibitors of histone demethylase |
CA2944401A1 (en) | 2014-04-03 | 2015-10-08 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
KR20240038809A (en) | 2014-04-14 | 2024-03-25 | 아비나스 오퍼레이션스, 인코포레이티드 | Imide-based modulators of proteolysis and associated methods of use |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
US10195208B2 (en) | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
AU2015303835B2 (en) | 2014-08-12 | 2020-04-09 | Monash University | Lymph directing prodrugs |
BR112017003442A2 (en) | 2014-08-27 | 2017-11-28 | Gilead Sciences Inc | compounds and methods for inhibiting histone demethylases |
EP2995630A1 (en) | 2014-09-09 | 2016-03-16 | Dublin Institute of Technology | Hybrid compounds formed from ionic liquids and uses thereof in ion selective electrodes |
US20170281624A1 (en) | 2014-09-13 | 2017-10-05 | Novartis Ag | Combination therapies of alk inhibitors |
EA201790737A1 (en) | 2014-10-03 | 2017-08-31 | Новартис Аг | COMBINED THERAPY |
EP3262049B1 (en) | 2015-02-27 | 2022-07-20 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
KR20170129802A (en) | 2015-03-10 | 2017-11-27 | 아두로 바이오테크, 인코포레이티드 | Compositions and methods for activating "stimulating factors" -dependent signaling of interferon genes |
CN107531660A (en) | 2015-03-13 | 2018-01-02 | 福马治疗股份有限公司 | α cinnamide compounds and composition as HDAC8 inhibitor |
CN108601764A (en) | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | The Compounds and methods for of enhancing degradation for target protein |
DK3297992T3 (en) | 2015-05-22 | 2020-04-20 | Chong Kun Dang Pharmaceutical Corp | Heterocyclic alkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same |
WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
CA2995036A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
WO2017032281A1 (en) * | 2015-08-21 | 2017-03-02 | 苏州晶云药物科技有限公司 | Novel crystal forms of panobinostat lactate |
EP3344624B8 (en) | 2015-09-02 | 2023-11-29 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
CA2997106C (en) | 2015-09-08 | 2024-06-04 | Monash University | Lymph directing prodrugs |
US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
FI3364958T3 (en) | 2015-10-23 | 2023-04-06 | Navitor Pharm Inc | Modulators of sestrin-gator2 interaction and uses thereof |
AU2016349781A1 (en) | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
ITUB20155193A1 (en) | 2015-11-03 | 2017-05-03 | Italfarmaco Spa | Physically and chemically stable oral Givinostat suspensions |
JP6864296B2 (en) | 2015-12-14 | 2021-04-28 | エックス4 ファーマシューティカルズ, インコーポレイテッド | How to treat cancer |
EP3389652B1 (en) | 2015-12-14 | 2022-09-28 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
EP3389664A4 (en) | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | Caffeine inhibitors of mthfd2 and uses thereof |
ES2935834T3 (en) | 2015-12-22 | 2023-03-10 | X4 Pharmaceuticals Inc | Methods for treating immunodeficiency disease |
CN105732467A (en) * | 2016-01-13 | 2016-07-06 | 深圳市康立生生物科技有限公司 | Preparation method of panobinostat |
PL3884939T3 (en) | 2016-03-09 | 2024-02-26 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
US11014882B2 (en) * | 2016-03-09 | 2021-05-25 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
CN109195593A (en) | 2016-03-15 | 2019-01-11 | 奥莱松基因组股份有限公司 | For treating the combination of the LSD1 inhibitor of solid tumor |
CN109462980B (en) | 2016-03-15 | 2022-02-08 | 奥莱松基因组股份有限公司 | Combination of LSD1 inhibitors for the treatment of hematologic malignancies |
EP3440112A4 (en) | 2016-04-08 | 2019-10-09 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US11261187B2 (en) | 2016-04-22 | 2022-03-01 | Duke University | Compounds and methods for targeting HSP90 |
AR108257A1 (en) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | POLYMORPHIC FORMS OF 3- [2-BUTIL-1- (2-DIETILAMINO-ETIL) -1H-BENCIMIDAZOL-5-IL] -N-HYDROXY-ACRYLAMIDE AND USES OF THE SAME |
CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
CN109562107A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Heterocycle degron body for target protein degradation |
JP7054529B2 (en) | 2016-06-21 | 2022-04-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | CXCR4 inhibitor and its use |
EP3471726A4 (en) | 2016-06-21 | 2019-10-09 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
CA3068059A1 (en) * | 2016-06-21 | 2017-12-28 | The University Of Melbourne | Activators of hiv latency |
US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
WO2018015493A1 (en) | 2016-07-20 | 2018-01-25 | Royal College Of Surgeons In Ireland | Metal complexes having therapeutic applications |
WO2018039205A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating breast cancer |
WO2018039203A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating multiple myeloma |
WO2018054960A1 (en) | 2016-09-21 | 2018-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl |
US10207998B2 (en) | 2016-09-29 | 2019-02-19 | Duke University | Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof |
US10927083B2 (en) | 2016-09-29 | 2021-02-23 | Duke University | Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase |
CA3040155C (en) | 2016-10-11 | 2024-01-16 | Euro-Celtique S.A. | Compound for use in the treatment of hodgkin lymphoma |
ES2930198T3 (en) | 2016-10-14 | 2022-12-07 | Nimbus Lakshmi Inc | TYK2 inhibitors and uses thereof |
WO2018075937A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
WO2018089499A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF |
JP2019535839A (en) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | Exosomes for the delivery of therapeutic agents |
US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
CN110603261A (en) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | Peptide derivatives having novel bond structure |
EP3565638B8 (en) | 2017-01-06 | 2024-04-10 | BicycleRD Limited | Bicycle conjugate for treating cancer |
CN111386263A (en) | 2017-02-08 | 2020-07-07 | 达纳-法伯癌症研究所有限公司 | Modulation of chimeric antigen receptors |
TWI783978B (en) | 2017-03-08 | 2022-11-21 | 美商林伯士拉克許米公司 | Tyk2 inhibitors, uses, and methods for production thereof |
EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
JOP20180036A1 (en) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | Novel ferroportin-inhibitor salts |
US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
UY37695A (en) | 2017-04-28 | 2018-11-30 | Novartis Ag | BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME |
CN107141244B (en) * | 2017-05-08 | 2019-11-19 | 潍坊医学院 | Indolebutyric acid class inhibitors of histone deacetylase and its preparation method and application |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
CN111032678A (en) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | Bicyclic peptide ligands with detectable moieties and uses thereof |
US11046698B2 (en) | 2017-07-28 | 2021-06-29 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
JP2020529427A (en) | 2017-08-04 | 2020-10-08 | バイスクルテクス・リミテッド | Bicyclic peptide ligand specific for CD137 |
KR101977970B1 (en) | 2017-08-04 | 2019-05-14 | 중원대학교 산학협력단 | Novel benzamide derivatives compounds, manufacturing method thereof, and phamaceutical composition for preventing and treating cancer containing the same |
US20200283482A1 (en) | 2017-08-14 | 2020-09-10 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
WO2019034866A1 (en) | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
IL295603B2 (en) | 2017-09-22 | 2024-03-01 | Kymera Therapeutics Inc | Protein degraders and uses thereof |
US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
WO2019084026A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof |
WO2019084030A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-hydroxypyrrolidin-2-yl)-hydroxamate compounds and methods of use thereof |
WO2019083960A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | Peptide vaccines and hdac inhibitors for treating multiple myeloma |
AU2018353984A1 (en) | 2017-10-24 | 2020-05-07 | Oncopep, Inc. | Peptide vaccines and pembrolizumab for treating breast cancer |
US10683297B2 (en) | 2017-11-19 | 2020-06-16 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
EP3730483B1 (en) | 2017-12-21 | 2023-08-30 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Class of pyrimidine derivative kinase inhibitors |
AU2018396142A1 (en) | 2017-12-26 | 2020-07-16 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
CA3083040A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
IL301089A (en) | 2018-01-29 | 2023-05-01 | Vertex Pharma | Gcn2 inhibitors and uses thereof |
TW201940481A (en) | 2018-01-29 | 2019-10-16 | 美商維泰克斯製藥公司 | GCN2 inhibitors and uses thereof |
BR112020016314A2 (en) | 2018-02-12 | 2020-12-15 | Inimmune Corporation | PHARMACEUTICALLY ACCEPTABLE COMPOUNDS OR SALTS, PHARMACEUTICAL COMPOSITION, KIT, AND, METHODS FOR ELICITATING, INTENSIFYING OR MODIFYING AN IMMUNOLOGICAL RESPONSE, TO TREAT, PREVENT OR REDUCE THE SUSCETIBILITY TO CANCER, TO REDUCE, UNDERSTAND TREAT, PREVENT OR REDUCE SUSCEPTIBILITY TO AN ALLERGY, TO TREAT, PREVENT OR REDUCE SUSCETIBILITY TO AUTOIMMUNE AFFECTION, TO TREAT, PREVENT OR REDUCE SUSCETIBILITY IN A SUBJECT TO BACTERIAL INFECTION, ALTERNATE, VENEER, NAVAL, NAVARI TREAT, PREVENT OR REDUCE SUSCEPTIBILITY TO AUTOIMMUNITY, ALLERGY, ISCHEMIA OR SEPSIS REPERFUSION, TO TREAT, PREVENT OR REDUCE THE GRAVITY OF EPILETIC ATTACKS AND TO TREAT, PREVENT OR REDUCE THE MACANTIC HERITAGE OF HERITAGE, |
AU2019229258B2 (en) | 2018-02-27 | 2023-09-14 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of TCR-Nck interaction |
WO2019183523A1 (en) | 2018-03-23 | 2019-09-26 | Genentech, Inc. | Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl) |
CN118480030A (en) | 2018-04-13 | 2024-08-13 | 阿尔维纳斯运营股份有限公司 | Cerebulin ligands and bifunctional compounds comprising same |
MX2020011089A (en) | 2018-04-24 | 2020-11-06 | Merck Patent Gmbh | Antiproliferation compounds and uses thereof. |
US11059826B2 (en) | 2018-04-24 | 2021-07-13 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
JP2021533181A (en) | 2018-06-13 | 2021-12-02 | アンフィスタ セラピューティクス リミテッド | Bifunctional molecule for targeting UchL5 |
WO2019238886A1 (en) | 2018-06-13 | 2019-12-19 | University Of Dundee | Bifunctional molecules for targeting usp14 |
CN112533918A (en) | 2018-06-13 | 2021-03-19 | 安菲斯塔治疗有限责任公司 | Bifunctional molecules for targeting Rpn11 |
LT3813946T (en) | 2018-06-15 | 2024-07-10 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
CN108752255A (en) * | 2018-07-19 | 2018-11-06 | 重庆医科大学 | A kind of preparation method of pabishta and its key intermediate |
WO2020023628A1 (en) | 2018-07-24 | 2020-01-30 | Hygia Pharmaceuticals, Llc | Compounds, derivatives, and analogs for cancer |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
EP3866789A4 (en) | 2018-10-15 | 2022-07-06 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
US10919937B2 (en) | 2018-10-23 | 2021-02-16 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
CN109574936B (en) * | 2018-11-23 | 2022-02-22 | 沈阳药科大学 | Hydroxamic acid compound with HDAC6 inhibitory activity and application thereof |
CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
CN113271938A (en) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | TYK2 inhibitors and uses thereof |
EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
CN113348021A (en) | 2019-01-23 | 2021-09-03 | 林伯士拉克许米公司 | TYK2 inhibitors and uses thereof |
WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
AU2020253990A1 (en) | 2019-04-02 | 2021-10-28 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
CA3135802A1 (en) | 2019-04-05 | 2020-10-08 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
MX2021014441A (en) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Tead inhibitors and uses thereof. |
GB201913123D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
US11845724B2 (en) | 2019-09-11 | 2023-12-19 | Vincere Biosciences, Inc. | USP30 inhibitors and uses thereof |
GB201913122D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
GB201913124D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
GB201913121D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
EP3798250A1 (en) | 2019-09-25 | 2021-03-31 | University College Dublin | Hyperbranched cationic polymers useful as nucleic acid delivery vectors for transfecting |
CA3151988A1 (en) | 2019-09-25 | 2021-04-01 | Wenxin Wang | Nanoparticle compositions for gene therapy |
US20220401564A1 (en) * | 2019-11-06 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Selective histone deacetylase (hdac) degraders and methods of use thereof |
EP4069223A4 (en) | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | Rapamycin analogs and uses thereof |
WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
JP2023509366A (en) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス, インコーポレイテッド | IRAK dissolving agents and their uses |
TW202136240A (en) | 2019-12-19 | 2021-10-01 | 美商亞文納營運公司 | Compounds and methods for the targeted degradation of androgen receptor |
CA3162502A1 (en) | 2019-12-23 | 2021-07-01 | Yi Zhang | Smarca degraders and uses thereof |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
KR20220149534A (en) | 2020-02-05 | 2022-11-08 | 퓨어테크 엘와이티, 아이엔씨. | Lipid prodrugs of neurosteroids |
IT202000004075A1 (en) | 2020-02-27 | 2021-08-27 | Flamma Spa | PROCESS FOR THE PREPARATION OF PANOBINOSTAT |
CN115515685A (en) | 2020-03-03 | 2022-12-23 | 皮克医疗公司 | EIF4E inhibitor and application thereof |
WO2021233534A1 (en) | 2020-05-20 | 2021-11-25 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
WO2021185844A1 (en) | 2020-03-16 | 2021-09-23 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
BR112022018678A2 (en) | 2020-03-19 | 2022-11-01 | Kymera Therapeutics Inc | MDM2 DEGRADATORS AND THEIR USES |
TW202210483A (en) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Crystalline forms of irak degraders |
EP4192509A1 (en) | 2020-08-05 | 2023-06-14 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
CN116234931A (en) | 2020-08-17 | 2023-06-06 | 拜斯科技术开发有限公司 | Bicyclic conjugates with specificity for NECTIN-4 and uses thereof |
US11999964B2 (en) | 2020-08-28 | 2024-06-04 | California Institute Of Technology | Synthetic mammalian signaling circuits for robust cell population control |
WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
CN117015531A (en) | 2020-12-02 | 2023-11-07 | 医肯纳肿瘤学公司 | TEAD inhibitors and uses thereof |
KR20230137889A (en) | 2020-12-18 | 2023-10-05 | 암피스타 테라퓨틱스 엘티디 | Novel bifunctional molecules for targeted protein degradation |
GB202020359D0 (en) | 2020-12-22 | 2021-02-03 | Midatech Pharma Wales Ltd | Pharmaceutical compositions and use thereof in combination therapy for brain cancer |
KR20230152692A (en) | 2021-02-02 | 2023-11-03 | 리미널 바이오사이언시스 리미티드 | GPR84 antagonists and their uses |
MX2023009060A (en) | 2021-02-02 | 2023-09-29 | Liminal Biosciences Ltd | Gpr84 antagonists and uses thereof. |
JP2024514879A (en) | 2021-04-16 | 2024-04-03 | イケナ オンコロジー, インコーポレイテッド | MEK inhibitors and their uses |
EP4392422A1 (en) | 2021-08-25 | 2024-07-03 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
WO2023028238A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
GB2611043A (en) | 2021-09-22 | 2023-03-29 | Univ Dublin City | A cis-platinum(II)-oligomer hybrid |
CN118632688A (en) | 2021-11-19 | 2024-09-10 | 布朗卡布努斯有限公司 | Composition comprising a therapeutically active agent packaged in a drug delivery vehicle |
WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023194441A1 (en) | 2022-04-05 | 2023-10-12 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
GB2617409B (en) | 2022-04-27 | 2024-06-26 | Cancertain Ltd | Method for predicting responsiveness to therapy |
TW202404581A (en) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Mek inhibitors and uses thereof |
WO2023242597A1 (en) | 2022-06-16 | 2023-12-21 | Amphista Therapeutics Limited | Bifunctional molecules for targeted protein degradation |
TW202415650A (en) | 2022-08-02 | 2024-04-16 | 英商利米那生物科技有限公司 | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
WO2024028363A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
WO2024030441A1 (en) | 2022-08-02 | 2024-02-08 | National University Corporation Hokkaido University | Methods of improving cellular therapy with organelle complexes |
TW202416972A (en) | 2022-08-02 | 2024-05-01 | 英商利米那生物科技有限公司 | Substituted pyridone gpr84 antagonists and uses thereof |
WO2024041744A1 (en) | 2022-08-26 | 2024-02-29 | Biodexa Ltd. | Combination therapy for brain cancer |
WO2024112894A1 (en) | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
WO2024184266A1 (en) | 2023-03-03 | 2024-09-12 | Ionctura Sa | Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700811A (en) * | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
JP3342485B2 (en) * | 1991-12-10 | 2002-11-11 | 塩野義製薬株式会社 | Aromatic sulfonamide hydroxamic acid derivatives |
US5569668A (en) * | 1995-03-29 | 1996-10-29 | Webster; John M. | Indole derivatives with antibacterial and antimycotic properties |
US5722242A (en) * | 1995-12-15 | 1998-03-03 | Borealis Technical Limited | Method and apparatus for improved vacuum diode heat pump |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
JPH10182583A (en) | 1996-12-25 | 1998-07-07 | Mitsui Chem Inc | New hydroxamic acid derivative |
AUPO721997A0 (en) * | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
US6127392A (en) * | 1997-08-05 | 2000-10-03 | American Home Products Corporation | Anthranilic acid analogs |
WO1999007669A1 (en) | 1997-08-05 | 1999-02-18 | American Home Products Corporation | Anthranilic acid analogs |
ES2228119T3 (en) | 1998-10-19 | 2005-04-01 | Methylgene, Inc. | MODULATION OF THE EXPRESSION OF DNA-METHYL-TRANFERASE THROUGH COMBINATION THERAPY. |
US6110922A (en) | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
UA74781C2 (en) | 1999-04-02 | 2006-02-15 | Abbott Lab | Antiinflammatory and immumosuppressive compounds inhibiting cell adhesion |
CN1378450A (en) | 1999-09-08 | 2002-11-06 | 斯隆-凯特林癌症研究院 | Novel class of cytodifferentiating agents and histone deactylase inhibitors, and methods of use thereof |
GB9922173D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
EP1233958B1 (en) * | 1999-11-23 | 2011-06-29 | MethylGene Inc. | Inhibitors of histone deacetylase |
DE60026733T2 (en) | 1999-12-08 | 2006-11-02 | AXYS Pharmaceuticals, Inc., South San Francisco | HISTONE DEACETYLASE-8 PROTEINS, NUCLEIC ACIDS AND METHODS OF USE |
TW427572U (en) * | 1999-12-17 | 2001-03-21 | Hon Hai Prec Ind Co Ltd | Electrical connector |
EP1280764B1 (en) | 2000-03-24 | 2010-11-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
EP1438404A2 (en) * | 2000-03-24 | 2004-07-21 | Methylgene, Inc. | Inhibition of specific histone deacetylase isoforms |
EP1314721A1 (en) * | 2000-08-31 | 2003-05-28 | Wakunaga Pharmaceutical Co., Ltd. | Novel propenohydroxamic acid derivatives |
PE20020354A1 (en) * | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
MXPA03003002A (en) | 2000-10-05 | 2004-12-06 | Fujisawa Pharmaceutical Co | Benzamide compounds as apo b secretion inhibitors. |
SE0101386D0 (en) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | New compounds |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
HUP0500573A2 (en) | 2001-08-11 | 2005-11-28 | Bristol-Myers Squibb Pharma Company | Triphenyl-ethylene derivatives as selective estrogen receptor modulators and pharmaceutical compositions containing the same |
US6706686B2 (en) * | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
DE10152764A1 (en) * | 2001-10-29 | 2003-05-08 | Linde Ag | Valve for cryogenic media |
-
2001
- 2001-08-28 PE PE2001000866A patent/PE20020354A1/en not_active Application Discontinuation
- 2001-08-30 IL IL15457401A patent/IL154574A0/en unknown
- 2001-08-30 SK SK242-2003A patent/SK287609B6/en not_active IP Right Cessation
- 2001-08-30 WO PCT/EP2001/010037 patent/WO2002022577A2/en active IP Right Grant
- 2001-08-30 PT PT01960717T patent/PT1318980E/en unknown
- 2001-08-30 NZ NZ524365A patent/NZ524365A/en not_active IP Right Cessation
- 2001-08-30 PL PL361408A patent/PL221738B1/en unknown
- 2001-08-30 BR BRPI0113669A patent/BRPI0113669B8/en not_active IP Right Cessation
- 2001-08-30 SI SI200130803T patent/SI1318980T1/en unknown
- 2001-08-30 MX MXPA03001832A patent/MXPA03001832A/en active IP Right Grant
- 2001-08-30 ES ES01960717T patent/ES2292610T3/en not_active Expired - Lifetime
- 2001-08-30 MY MYPI20014079A patent/MY136892A/en unknown
- 2001-08-30 AU AU2001282129A patent/AU2001282129B2/en not_active Ceased
- 2001-08-30 KR KR1020037002446A patent/KR100585484B1/en active Protection Beyond IP Right Term
- 2001-08-30 CN CNB018150675A patent/CN1300110C/en not_active Expired - Lifetime
- 2001-08-30 RU RU2003108857A patent/RU2302408C3/en not_active IP Right Cessation
- 2001-08-30 DK DK01960717T patent/DK1318980T3/en active
- 2001-08-30 CA CA2420899A patent/CA2420899C/en not_active Expired - Lifetime
- 2001-08-30 JP JP2002526830A patent/JP4012819B2/en not_active Expired - Lifetime
- 2001-08-30 AT AT01960717T patent/ATE376999T1/en active
- 2001-08-30 EP EP01960717A patent/EP1318980B1/en not_active Expired - Lifetime
- 2001-08-30 AU AU8212901A patent/AU8212901A/en active Pending
- 2001-08-30 CZ CZ20030573A patent/CZ302707B6/en not_active IP Right Cessation
- 2001-08-30 AR ARP010104140A patent/AR035057A1/en active IP Right Grant
- 2001-08-30 HU HU0300880A patent/HU229796B1/en active Protection Beyond IP Right Term
- 2001-08-30 DE DE60131179T patent/DE60131179T2/en not_active Expired - Lifetime
- 2001-08-30 EP EP07115019A patent/EP1870399A1/en not_active Withdrawn
- 2001-08-31 TW TW090121617A patent/TWI286544B/en not_active IP Right Cessation
- 2001-08-31 US US09/944,275 patent/US6552065B2/en not_active Expired - Lifetime
-
2002
- 2002-11-19 US US10/299,518 patent/US6833384B2/en active Active
-
2003
- 2003-02-20 IL IL154574A patent/IL154574A/en active IP Right Grant
- 2003-02-21 ZA ZA200301423A patent/ZA200301423B/en unknown
- 2003-02-25 NO NO20030867A patent/NO324942B1/en not_active IP Right Cessation
- 2003-02-25 EC EC2003004492A patent/ECSP034492A/en unknown
- 2003-11-19 HK HK03108445A patent/HK1057746A1/en not_active IP Right Cessation
-
2004
- 2004-11-09 US US10/984,501 patent/US7067551B2/en not_active Expired - Lifetime
-
2006
- 2006-04-20 US US11/408,129 patent/US20060189674A1/en not_active Abandoned
-
2007
- 2007-12-19 CY CY20071101619T patent/CY1107839T1/en unknown
-
2008
- 2008-03-11 US US12/045,885 patent/US20080176849A1/en not_active Abandoned
-
2015
- 2015-11-30 NL NL300778C patent/NL300778I2/nl unknown
- 2015-12-01 LU LU92890C patent/LU92890I2/en unknown
- 2015-12-03 BE BE2015C062C patent/BE2015C062I2/fr unknown
- 2015-12-08 FR FR15C0086C patent/FR15C0086I2/en active Active
- 2015-12-10 NO NO2015026C patent/NO2015026I2/en not_active IP Right Cessation
- 2015-12-14 CY CY2015053C patent/CY2015053I1/en unknown
- 2015-12-16 HU HUS1500068C patent/HUS1500068I1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6552065B2 (en) | Deacetylase inhibitors | |
AU2001282129A1 (en) | Hydroxamate derivatives useful as deacetylase inhibitors | |
KR20080035683A (en) | Method of use of deacetylase inhibitors | |
EP1443967B1 (en) | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | |
KR100464526B1 (en) | Sodium-hydrogen exchanger type 1 inhibitor crystals | |
AU2008204928B2 (en) | Formulations of deacetylase inhibitors | |
WO2008137630A1 (en) | Use of hdac inhibitors for the treatment of gastrointestinal cancers | |
JP2010526830A (en) | Use of HDAC inhibitors for the treatment of melanoma |